Section 3 of 6
Product information and disease description
361 evidence topics · 144 sources
Product description
Phase of product development
Summary: regulatory history and status
- Current status: under FDA review. Apnimed submitted a New Drug Application (NDA) for Oxnimbi (AD109) through the section 505(b)(2) pathway in April 2026; the FDA accepted it for review in July 2026 and assigned a PDUFA goal date of February 28, 2027. The 10-Q states that the review cycle is targeted at 10 months from the April 2026 submission. No launch date has been stated.
- Designations: Fast Track designation for the treatment of OSA in May 2022.
- Proprietary name: Oxnimbi is a proposed name. The prospectus states that the FDA conditionally approved it in May 2025, reconfirmed it in June 2026, and that it is pending approval of the NDA; the third quarter 2026 release states that it remains subject to final FDA review and may change.
- Combination product requirement: as a fixed-dose combination, the product generally requires the sponsor to demonstrate the contribution of each component to the claimed effect and the safety and efficacy of the combination as a whole.
- FDA questions: at the pre-NDA meeting, the FDA gave feedback on the “clinical meaningfulness of certain endpoint results”, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed to show a clinically meaningful benefit. Apnimed states that it responded in the NDA. The third quarter 2026 Form 10-Q states that the FDA, in its acceptance letter and later communications, has raised questions regarding the adequacy of the NDA and has requested additional information, data, or analyses on the nonclinical, clinical, or CMC areas; its risk factors name the adequacy of stability data and the manufacturing process.
- Development completed: 13 phase 1, 2, and 3 trials, including two registrational phase 3 trials (LunAIRo in the United States and SynAIRgy in the United States and Canada).
- Earlier timing statements, now superseded: the May 2025 and July 2025 topline releases planned an NDA submission by early 2026; the March 2026 release expected submission in the second quarter of 2026; the April 2026 debt financing release expected it later that quarter; the May 2026 SynAIRgy publication release expected a PDUFA target action date in the first quarter of 2027, subject to FDA acceptance. The July 2026 acceptance, with a goal date of February 28, 2027, replaced these statements.
Regulatory status: Under review; NDA submitted April 2026 and accepted July 2026, with a PDUFA goal date of February 2027
Launch
No evidence found.
Review timeline: 10-month review from submission
Regulatory pathway: section 505(b)(2) NDA
FDA questions raised in the acceptance letter and during review
Clinical development completed: two phase 3 trials and 13 trials overall
PDUFA date expectation, May 2026, superseded in July 2026
NDA submission timing, April 2026, superseded in April 2026
NDA submission timing, March 2026, superseded in April 2026
NDA submission timing, July 2025, superseded in March 2026
NDA submission timing, May 2025, superseded in March 2026
Product information
Generic, brand name and therapeutic class of product
Established name and proposed proprietary name
Therapeutic class: anti-apneic neuromuscular modulator combining an antimuscarinic and a norepinephrine reuptake inhibitor
Aroxybutynin: the R-enantiomer of oxybutynin, not previously approved
Dosage forms and strengths
Strengths filed in the NDA: aroxybutynin and atomoxetine base with hydrochloride equivalents
Dosage form: fixed-dose oral tablet taken once nightly
Strength notation in publications: aroxybutynin 2.5 mg/atomoxetine 75 mg
Phase 3 investigational product supply: run-in blister pack and target-dose bottle
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
No evidence found.
Indication
Proposed indication under FDA review: adults with obstructive sleep apnea
Intended disease severity range: mild, moderate, and severe
Phase 3 population: adults intolerant to or refusing PAP therapy
“SynAIRgy enrolled adults with mild-to-severe OSA who were intolerant to or refused PAP therapy into a randomized, double-blind, placebo-controlled, 26-week parallel-arm trial of AD109 vs placebo across 69 centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacology
Mechanism of action
Combination: company description of the target and the two components
Combination: noradrenergic excitation and antimuscarinic disinhibition of the hypoglossal motor nucleus
“AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atomoxetine, a selective norepinephrine reuptake inhibitor, was expected to increase synaptic norepinephrine and enhance central excitatory drive to upper airway motor neurons, thereby improving dilator muscle tone. Aroxybutynin, a selective antimuscarinic agent, was hypothesized to reduce muscarinic inhibition of HMN activity (Figures 1 and 2). Together, this dual mechanism was designed to stabilize upper airway muscle activation across NREM and REM sleep and mitigate sleep-related relaxation of the airway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combination: proposed mechanism by which aroxybutynin offsets the wake-promoting effect of atomoxetine, not yet shown in animal models
Aroxybutynin: the R-enantiomer of racemic oxybutynin
“AD109 refined the original combination by substituting oxybutynin with aroxybutynin, the R-enantiomer that mediates most of oxybutynin’s antimuscarinic actions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Concentrating the pharmacologic activity in a single active stereoisomer allows for equivalent effects on the upper airway at a lower total dose, with the potential for fewer off-target effects and better overall tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oxybutynin label: muscarinic antagonism residing predominantly in the R-isomer
Atomoxetine label: selective inhibition of the presynaptic norepinephrine transporter
Pharmacodynamics
Atomoxetine plus racemic oxybutynin, single night: genioglossus responsiveness and AHI (hypopneas with 3% desaturation or arousal)
“ato–oxy lowered AHI by 63% (34–86%), from 28.5 (10.9–51.6) events/h to 7.5 (2.4–18.6) events/h (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genioglossus responsiveness increased approximately threefold, from 2.2 (1.1–4.7)%/cm H2O on placebo to 6.3 (3.0 to 18.3)%/cm H2O on ato–oxy (P < 0.001). Neither atomoxetine nor oxybutynin reduced the AHI when administered separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hypopneas were defined as reduction in flow of 30% or more from baseline, lasting at least 10 seconds, and were associated with an arousal from sleep or an oxyhemoglobin desaturation 3% or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine plus racemic oxybutynin: effects on endotypic traits
“Compared with placebo, ato-oxy increased Vpassive by 73 [54 to 91]%eupnea (P < .001) and muscle compensation by 29 [8 to 51]%eupnea (P = .012), reduced the arousal threshold by –9 [–14 to –3]% (P = .022) and LG1 by –11 [–22 to 2]% (P = .022). Atomoxetine alone significantly reduced arousal threshold and LG1. Both agents alone improved collapsibility (Vpassive) but not muscle compensation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine alone versus atomoxetine plus racemic oxybutynin (AD036), home sleep studies (hypopneas with 4% desaturation)
“The apnea–hypopnea index (AHI) from a median (interquartile range) of 14.2 (5.4 to 22.3) events/h on placebo to 6.2 (2.8 to 13.6) with AD036 and 4.8 (1.4 to 11.6) with atomoxetine alone (p < .0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD036, but not atomoxetine alone, reduced the respiratory arousal index and improved ventilation at the respiratory arousal threshold (greater Vactive). There was a trend for total sleep time to be decreased more with atomoxetine alone than with AD036.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atomoxetine may account for the majority of improvement in OSA severity, while the addition of oxybutynin may mitigate the disruptive effect of atomoxetine on sleep and further improve ventilation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 4% oxygen desaturation criterion was used for scoring of hypopneas and subsequent calculation of the AHI, and for calculation of the oxygen desaturation index (ODI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Choice of antimuscarinic: atomoxetine with solifenacin or biperiden (AASM scoring)
“Neither drug combination altered the apnea/hypopnea index versus placebo (P = 0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Atomoxetine + biperiden hydrochloride reduces perceived sleepiness, and atomoxetine + solifenacin modestly improves upper airway function in people with OSA but to a lesser extent versus recently published atomoxetine + oxybutynin (broad M-subtype receptor selectivity) findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All overnight in-laboratory sleep studies (polysomnography) were performed according to American Academy of Sleep Medicine guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contribution of the antimuscarinic component to upper airway activity and sleep consolidation
“However, it has become clear, after multiple similar findings, that the SNRIs (atomoxetine or reboxetine) have the most important stimulatory action on the pharyngeal dilator muscles, while the antimuscarinic component has a smaller such effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A second important contribution of the anticholinergic agent in the ato-oxy combination was discovered to be the mitigation of the wake-promoting effects caused by the SNRIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oxybutynin was also found to attenuate a reduction in arousal threshold observed with atomoxetine monotherapy, raising the possibility that blocking muscarinic signaling blunts the behavioral/arousal expression of noradrenergic drive48 allowing for HMN activations while maintaining sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AD109 versus atomoxetine alone over 4 weeks: respiratory parameters and total sleep time (MARIPOSA)
“AD109 did not differ significantly from atomoxetine alone (Ato75) for most respiratory parameters, suggesting that the noradrenergic activity of atomoxetine is primarily responsible for the effect of AD109 on upper airway obstruction. However, Ato75 was more likely to disturb sleep than AD109 based on objective and subjective measurements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total sleep time (TST) did not change with AD109 compared with placebo. However, Ato75 reduced TST by 21.5 (8.6–34.3) minutes compared with placebo (P = 0.001) and by 23.93 (8.89–38.98) and 16.09 (1.24–30.94) minutes compared with AD109 2.5/75 mg and 5/75 mg, respectively (P = 0.002 and P = 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AD109 dose response after a single night, APC-004 (hypoxic burden and AHI with 4% desaturation)
Apnea index and hypopnea index (4% desaturation criterion) in the phase 3 trials, on-treatment estimand: company exploratory analysis
REM sleep and body mass index changes in the phase 3 trials
“AD109 was associated with a reduction in REM sleep, consistent with the established effects of noradrenergic, serotonergic, and tryciclic antidepressant agents. The clinical significance of pharmacologically driven REM reduction remains uncertain, and existing evidence suggests that it is not associated with impairments in cognitive performance or vigilance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine label: cardiac electrophysiology
Oxybutynin label: pharmacodynamic effects on the bladder
Pharmacokinetics
Phase 1 bridging study: aroxybutynin 2.3 mg versus racemic oxybutynin 5 mg (APC-001)
Phase 1: components given alone and in combination, and time to maximum concentration (APC-001 and APC-002)
Metabolic pathways of the two components
Atomoxetine label: pharmacokinetic parameters by CYP2D6 metabolizer type
| Parameter | Other CYP2D6 metabolizer types | CYP2D6 poor metabolizers |
|---|---|---|
| Accumulation | “1.1-fold” | “3.3-fold” |
| Absolute bioavailability | “63%” | “94%” |
| Median time to maximum concentration | “1 hour” | “2.5 hour” |
| Atomoxetine half-life | “5.2 hours” | “21.6 hours” |
| Atomoxetine apparent oral clearance | “0.35 L/hr/kg” | “0.03 L/hr/kg” |
| Primary metabolic pathways | “CYP2D6” | “Other CYP enzymes” |
Atomoxetine label: food effect, distribution, excretion, and exposure in CYP2D6 poor metabolizers
Oxybutynin label: R-oxybutynin and S-oxybutynin after a single 10 mg extended-release dose
| Parameter | R-oxybutynin | S-oxybutynin |
|---|---|---|
| Cmax (ng/mL), mean (SD) | “1.0 (0.6)” | “1.8 (1.0)” |
| Tmax (h), mean (SD) | “12.7 (5.4)” | “11.8 (5.3)” |
| Half-life (h), mean (SD) | “13.2 (6.2)” | “12.4 (6.1)” |
| AUCinf (ng•h/mL), mean (SD) | “21.3 (12.2)” | “39.5 (21.2)” |
Oxybutynin label: distribution, metabolism, and excretion
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for AD109
Not applicable.
Phase 3 trials: most common adverse events and serious adverse events (company statement)
Pooled phase 3 analysis: treatment-emergent adverse events
SynAIRgy: treatment-emergent adverse events in the safety analysis set
Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26
Pooled phase 3 analysis: overall treatment discontinuation by week 26
Treatment discontinuation due to adverse events and overall treatment discontinuation, SynAIRgy and LunAIRo
SynAIRgy: adverse events leading to treatment discontinuation
“The primary (occurring in ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment-emergent adverse event leading to treatment discontinuation | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
|---|---|---|
| Insomnia | “16 (4.9)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Urinary hesitation | “8 (2.5)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Nausea | “7 (2.2)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Erectile dysfunction/sexual dysfunction | “5 (1.5)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Dry mouth | “4 (1.2)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Hypertension | “3 (0.9)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Palpitations | “3 (0.9)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Urinary retention | “2 (0.6)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
Insomnia: discontinuation, onset, duration, and severity in the phase 3 trials
Cardiovascular effects: major adverse cardiovascular events and 24-hour ambulatory blood pressure in the phase 3 trials
Cardiovascular effects: heart rate and blood pressure, pooled phase 3 safety analysis set
| Measure | AD109 (n = 653) | Placebo (n = 646) | P value |
|---|---|---|---|
| Heart rate (beats/min), mean change from baseline to week 26, evening before PSG, mean (SD) | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate (beats/min), mean change from baseline to week 26, morning after PSG, mean (SD) | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Systolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.9 (12.0)” | “-1.2 (12.3)” | Not reported |
| Diastolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.7 (8.4)” | “-1.5 (7.8)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |
Cardiovascular effects: overnight heart rate over 4 weeks (MARIPOSA)
“Placebo-adjusted mean (95% confidence interval) change from baseline in overnight heart rate was slightly higher in all treatment groups: 7.7 (5.7–9.6), 5.1 (2.9–7.4), and 5.5 (3.3–7.1) beats/min for Ato75, Ad109 2.5/75 mg, and AD109 5/75 mg, respectively (Table 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular effects: populations excluded from the phase 3 trials and suggested caution
“However, while these changes were small on average, their clinical relevance may vary depending on individual patient characteristics, and careful consideration may be warranted in patients with uncontrolled or resistant hypertension, heart failure, or tachyarrhythmias. Notably, such patients were excluded from the clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events of special interest in the phase 3 trials
“Adverse events of special interest include urinary issues, cardiovascular symptoms, suicidal ideation, daytime sleepiness, motor vehicle accidents, and anticholinergic effects, with a focus on recording patient-reported experiences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attribution of adverse events to the noradrenergic and antimuscarinic components
“The adverse event profile is consistent with the mechanism of action of AD109. Noradrenergic stimulation may contribute to wake-promoting effects, including insomnia and nausea, while antimuscarinic activity may explain anticholinergic symptoms such as urinary hesitancy and dry mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 1 tolerability (APC-001 and APC-002)
Meta-analysis of atomoxetine combination trials: adverse events, dry mouth, and difficulty with urination
“While the ato group resulted in a significant increase in total AEs (RR = 1.65, 95% CI = 1.28, 2.13, P = 0.0001, I2 = 7%), dry mouth (29.2% vs 9.5%, P = 0.002) and difficulty with urination (10.7% vs 0.8%, P = 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine label: boxed warning for suicidal thoughts and behaviors in children and adolescents 6 years of age and older
Atomoxetine label: contraindications
Atomoxetine label: severe liver injury
Atomoxetine label: serious cardiovascular reactions
Atomoxetine label: increases in blood pressure and heart rate
Atomoxetine label: psychotic or manic symptoms, bipolar disorder screening, and aggressive behavior
Atomoxetine label: priapism and hypersensitivity reactions
Atomoxetine label: adverse reactions and discontinuation in adult ADHD studies
Oxybutynin label: anticholinergic central nervous system effects
Oxybutynin label: myasthenia gravis and autonomic neuropathy
Oxybutynin label: urinary retention and gastrointestinal adverse reactions
Oxybutynin label: most common adverse reactions
Special populations
Phase 3 trial population: age, cardiovascular, urinary, ocular, and pregnancy criteria
“The targeted study population is adults (≥18 years old, no upper age limit) with OSA of any severity defined as an AHI4>5 events/h (hypopneas scored when associated with 4% desaturation) with ≤25% central or mixed apneas (as proportion of total apneas and hypopneas), and PLM arousal index ≤15 events/h on the screening PSG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Potential participants with clinically significant or medically uncontrolled cardiovascular disease such as unstable atrial fibrillation, untreated or unstable coronary artery disease, heart failure, cerebrovascular events and resting heart rate >100 beats per min or blood pressure greater than 145/90 mmHg were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Narrow angle glaucoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Women who are pregnant or nursing” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Older men: age limits in the earlier trials because of urinary risk
“The trials reported above excluded male patients >65 due to concerns for higher risk of urinary problems with ato-oxy or AD109 in the older male population. Women over 65 years of age were allowed in the trial without any reported safety concerns.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroups by sex, weight class, and baseline severity in SynAIRgy
“In supportive analyses, AD109 improved AHI across diverse subgroups, such as those defined by sex, weight class, and baseline OSA severity (mild, moderate, and severe), supporting the generalizability of study findings to a broad spectrum of patients with OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reduced CYP2D6 activity: proposed contribution to variability in tolerability
“Tolerability may also have been influenced by interindividual variability in atomoxetine metabolism related to cytochrome P450 2D6 (CYP2D6) status. Individuals with reduced CYP2D6 activity may have higher systemic exposure to atomoxetine, which could contribute to variability in adverse events such as insomnia as well as in heart rate and blood pressure responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine label: CYP2D6 poor metabolizers
Atomoxetine label: hepatic impairment
Atomoxetine label: pregnancy and lactation
Oxybutynin label: renal and hepatic impairment
Oxybutynin label: pregnancy and lactation
Drug/Drug, drug/disease interactions
Effects of other drugs on AD109
Medications disallowed and allowed in the phase 3 trials
“Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GLP-1 receptor agonists: exposure to aroxybutynin and atomoxetine (APC-APN-201)
Atomoxetine label: strong CYP2D6 inhibitors
Atomoxetine label: monoamine oxidase inhibitors
Atomoxetine label: drugs that affect gastric pH and drugs highly bound to plasma protein
Oxybutynin label: other anticholinergic drugs
Effects of AD109 on other drugs
Atomoxetine label: albuterol and other beta2 agonists
Atomoxetine label: antihypertensive drugs and pressor agents
Atomoxetine label: CYP3A and CYP2D6 substrates and cytochrome P450 inhibition
Atomoxetine label: ethanol, methylphenidate, and drugs highly bound to plasma protein
Oxybutynin label: absorption of concomitant drugs and prokinetic agents
Dosing and administration
Dosage
Phase 3 regimen: 1-week run-in dose followed by the target dose, with no dose reduction
“AD109 dose was aroxybutynin 2.5 mg/atomoxetine 37.5 mg for week 1 and aroxybutynin 2.5 mg/atomoxetine 75 mg for the remaining weeks (dose reductions not permitted).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company statement on dose adjustment for tolerability in clinical practice
Atomoxetine dose relative to the maximum recommended ADHD dose
Higher aroxybutynin dose (5/75 mg) in dose finding (MARIPOSA)
“It is unclear why we did not see improvement with the higher dose of AD109, although higher rates of daytime symptoms such as dry mouth, urinary hesitation, constipation, and somnolence were reported with the higher dose of aroxybutynin, suggesting more tolerability issues with the AD109 5/75 mg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration
Once nightly at bedtime (company description)
Atomoxetine label: administration with respect to food
Oxybutynin label: administration of the extended-release tablet with respect to food
Access and distribution
Commercial readiness activities before a potential launch
Payer discussions to inform potential 2027 formulary inclusion
Planned distribution model: specialty pharmacy partners and a patient services hub
Planned field sales force and prescriber targets
Planned launch sequence by patient segment
Planned telehealth care pathways and durable medical equipment provider engagement
Manufacturing and commercial supply: contract manufacturers, no commercial supply agreements signed
Launch financing
Co-prescribed/Concomitant therapies
Positive airway pressure: initiation permitted during the phase 3 trials
“Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest. Dosing of AD109 or placebo can continue if PAP is initiated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Allowed and disallowed concomitant medications in the phase 3 trials
“Inhaled corticosteroid, and antidiabetics, including those associated with weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs used exclusively for weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Modafinil, armodafinil, solriamfetol, and pitolisant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Benzodiazepines, Z-drugs, DORAs, and trazodone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GLP-1 receptor agonists: pooled phase 3 exploratory analysis of weight change, participants taking a GLP-1 receptor agonist for diabetes
GLP-1 receptor agonists: company summary of concomitant use in the phase 3 trials
GLP-1 receptor agonists for weight loss: SynAIRgy exploratory cohort not analyzed
GLP-1 receptor agonists: open-label phase 2 co-administration study
Intended use alongside PAP or GLP-1 therapy
Effect of AD109 on quality measures
Product-specific effect on quality measures
No evidence found.
Merit-based Incentive Payment System 2026 measure 279: assessment of adherence to obstructive sleep apnea therapy
Merit-based Incentive Payment System 2026 measure 277: severity assessment at initial diagnosis
American Academy of Sleep Medicine adult obstructive sleep apnea quality measure set, 2022 update
“Two of the measures are currently included in the Merit-based Incentive Payment System (MIPS) program, which replaced the PQRS program, as a part of Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the purposes of this measure, evidence-based therapies include positive airway pressure, oral appliances (custom, titratable, Food and Drug Administration [FDA]–cleared appliances), positional therapies, upper airway surgeries, hypoglossal nerve stimulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Proportion of patients aged 18 years and older diagnosed with OSA that showed any improvement in their quality of life (QoL) from baseline within 1 year of starting treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Task Force reviewed this measure and agreed that, although there is not yet convergence on exactly which HRQoL instrument should be used, this is an important outcome to measure and document, as it will speak to the effectiveness of the assessments and treatment captured in the process measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The registry is approved by CMS as a Qualified Clinical Data Registry, for reporting quality measures as a part of the Quality Payment Program, a national quality reporting initiative that includes MIPS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product comparison
Head-to-head and indirect comparisons of AD109 with other OSA treatments
No evidence found.
Cross-trial context for AD109 and tirzepatide in an editorial on SynAIRgy
Comparator: tirzepatide in moderate-to-severe OSA with obesity, AHI with 4% desaturation hypopnea rule
“which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Review comparison of OSA pharmacotherapies, SynAIRgy figures under the treatment policy estimand
“Although AD109 demonstrated statistically significant therapeutic efficacy compared with placebo, the reductions in the AHI and oxygen desaturation index were only 3.3/h and 3.7/h, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings suggest that long-term tolerability and safety may remain challenging [28].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although tirzepatide is currently the only U.S. Food and Drug Administration-approved medication for OSA, it is expected that OSA-directed pharmacotherapy unrelated to weight loss that is effective for patients who refuse or discontinue PAP therapy may become available in the near future.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Investigational comparator: sulthiame in the FLOW phase 2 trial, AHI with 3% desaturation or arousal hypopnea rule
Investigational comparator: IHL-42X (dronabinol and acetazolamide) in the RePOSA phase 2 portion
Hypoglossal nerve stimulation manufacturer statement on AD109 as a competing product
Manufacturer description of competing treatments
Place of product in therapy
Disease description
Definition and etiology
Definition: upper airway collapse during sleep with apneas and hypopneas
Definition: narrowing of the upper airway that impairs ventilation during sleep
Diagnostic criteria: ICSD-3-TR criteria reproduced in the VA/DoD guideline
Diagnostic criteria: ICSD-3 definition and variability in the hypopnea definition
“The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, it should be noted that there is variability in the definition of a hypopnea event.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depending on which definition is used, the AHI may be considerably different in a given individual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity categories by respiratory event index
Risk factors: age, sex, body mass index, and menopause
Risk factors: demographic, anatomical, and behavioral factors
Risk factors: high-risk clinical populations
“High-risk patients include those who are obese, those with congestive heart failure, atrial fibrillation, treatment refractory hypertension, type 2 diabetes, stroke, nocturnal dysrhythmias, pulmonary hypertension, high-risk driving populations (such as commercial truck drivers), and those being evaluated for bariatric surgery (Consensus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity as a risk factor: share of adults with OSA who have obesity, AHI of 5 or more with 4% desaturation hypopnea rule (individual participant data meta-analysis with Apnimed authors)
“Obesity is a well-established risk factor for obstructive sleep apnea (OSA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OSA severity was quantified using the apnea-hypopnea index (AHI, all apneas plus hypopneas with ≥4% oxygen desaturation/hour).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 12,860 adults (mean ± SD age: 66.6 ± 7.3 years), 7222 (56.2%) had OSA (AHI ≥5 events/h) and 3309 (25.7%) had obesity (BMI ≥30 kg/m2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IPD meta-analysis showed 31.5% [95% CI: 16.8–48.5] of individuals with OSA had obesity and 44.4% [36.5–52.5] had overweight status (25 ≤ BMI < 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Odds ratios for OSA in subgroups of individuals with overweight and obesity compared to BMI <25 kg/m2 were 2.18 [1.73–2.76] and 4.84 [3.09–6.00], respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LG, L T-M, JY, JC work for Apnimed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Obstructive sleep apnea
Five-year incidence of AHI of at least 10 and at least 15 in a US community cohort (Cleveland Family Study, in-home sleep studies)
“Sleep-disordered breathing was defined by an AHI of at least 10 (mild to moderate) or of at least 15 (moderate).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-seven (16%) of 286 eligible participants, (95% confidence interval [CI], 13%-21%) had a second-study AHI of at least 10 and 29 (10%) participants (95% CI, 7%-14%) had a second-study AHI result of at least 15.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year incidence is about 7.5% for moderately severe SDB and 16% (or less) for mild to moderately severe SDB.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Predominance in men diminishes with increasing age, and by age 50 years, incidence rates among men and women are similar.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Weight change and incident moderate-to-severe sleep-disordered breathing, AHI of 15 or more (Wisconsin Sleep Cohort, 4-year intervals)
“Relative to stable weight, a 10% weight gain predicted an approximate 32% (95% confidence interval [CI], 20%-45%) increase in the AHI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A 10% weight loss predicted a 26% (95% CI, 18%-34%) decrease in the AHI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Five-year progression of the respiratory disturbance index with weight change (Sleep Heart Health Study)
“Men were more likely to have an increase in Respiratory Disturbance Index (RDI) with a given increase in weight than were women, and this was not explained by differences in starting weight, waist circumference, age, or ethnicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, SDB progressed over time, even in those with stable weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Predictors of five-year change in the respiratory disturbance index (Cleveland Family Study)
“Longitudinal change in the RDI varies nonuniformly with age, sex, and weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Older heavier men may experience the highest rate of increase in RDI over time and, thus, may benefit most from prospective monitoring.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosed incidence in English primary care and hospital records, 2010 to 2019 (ResMed-authored)
“Included adults had ≥ 1 OSA code and ≥ 12 months’ medical records before/after OSA diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of OSA increased from 46.74 per 100,000 in 2010 to 91.04 per 100,000 in 2019, with an average of 65.06 per 100,000 person-years over the period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall diagnosed incidence of OSA was 65.06 per 100,000 person-years (95% CI, 64.57-65.54).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“M. D., A. G., and N. A. are employees of ResMed and are ResMed shareholders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosed incidence in active-component US military members, 2004 to 2015
“The study identified 223,731 incident cases of OSA with an overall incidence rate of 139.2 per 10,000 person-years, between 2004 and 2015.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Rates increased more than 3-fold between 2004 and 2015.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of physician-reported sleep apnea after GLP-1 or dual agonist initiation in adults with obesity or type 2 diabetes (TriNetX records)
“We identified adult patients with obesity and/or type 2 diabetes mellitus never prescribed GLP-1 or dual agonist therapy (reference arm) and those new initiators of these medications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, GLP-1/dual agonists were associated with a 54% lower incidence of PRSA (HR, 0.46 [95% CI, 0.45-0.49]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Absence of US incidence data in a national projection model (ResMed-funded)
“Given the scarcity of data for obstructive sleep apnoea incidence in the USA, prevalence was used as a proxy to determine incidence by sex and age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Resmed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Obstructive sleep apnea
Company estimate: 80 million US adults aged 30 to 69 and one billion people worldwide (Clarivate study commissioned by Apnimed)
Company estimate: newly diagnosed, diagnosed and active in care, and diagnosed but untreated US adults (claims databases and a survey)
Company estimate: new diagnosis rate and initial target population, September 2026 corporate presentation
Company estimate: share of middle-aged and older adults with OSA who are not obese (third-party study supported by Apnimed)
US prevalence in 2024, AHI4 of 5 or more, adults aged 20 years and older (systematic review and obesity-adjusted projection by Clarivate and Apnimed authors)
“A literature-based systematic review was conducted to identify studies of OSA prevalence in adults using the AHI4 criteria (all apneas plus hypopneas associated with ≥4% oxygen desaturation).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OSA was defined as having an AHI4 ≥ 5 events/hr.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This translates to 32.4% overall prevalence in the US among adults aged 20 years and older, with 39.1% among males and 26.0% in females, adjusting for obesity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Self-reported diagnosed but untreated sleep apnea, US adults aged 18 to 90 (National Sleep Foundation survey with support from Inspire Medical Systems)
US prevalence in 2007 to 2010, AHI of 5 or more and 15 or more with 4% desaturation hypopnea rule, adults aged 30 to 70 (Wisconsin Sleep Cohort extrapolated to NHANES body mass index distributions)
“A discernible reduction in the sum of thoracic plus abdomen respiratory inductance plethysmography amplitude associated with a 4% or more reduction in oxyhemoglobin saturation defined a hypopnea event.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These estimated prevalence rates represent substantial increases over the last 2 decades (relative increases of between 14% and 55% depending on the subgroup).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Summing over age × sex × BMI strata, we estimated the overall prevalence of mild to severe SDB (AHI ≥5) to be 26% (95% confidence interval: 24, 28) among person 30–70 years of age for the recent time period (2007–2010).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, the estimated overall prevalence of moderate to worse SDB (AHI ≥15) was 10% (95% confidence interval: 8, 11).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We also estimate that 14% of men and 5% of women have an AHI ≥5 plus symptoms of daytime sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (ResMed-funded)
“A conversion algorithm was created for studies that did not use the American Academy of Sleep Medicine (AASM) 2012 scoring criteria to identify obstructive sleep apnoea, allowing determination of an equivalent apnoea-hypopnoea index (AHI) for publications that used different criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using AASM 2012 diagnostic criteria and AHI threshold values of five or more events per h and 15 or more events per h, we estimated that 936 million (95% CI 903–970) adults aged 30–69 years (men and women) have mild to severe obstructive sleep apnoea and 425 million (399–450) adults aged 30–69 years have moderate to severe obstructive sleep apnoea globally.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The number of affected individuals was highest in China, followed by the USA, Brazil, and India.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AVB, KV, and CMN are employees of ResMed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Funding ResMed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
US prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (country table of the global estimate)
| Measure | United States |
|---|---|
| Population aged 30–69 years | “163 246 772”View highlighted excerpt for this quote |
| AHI ≥5 events per h, n (%) | “54 131 654 (33·2%)”View highlighted excerpt for this quote |
| AHI ≥15 events per h, n (%) | “23 678 109 (14·5%)”View highlighted excerpt for this quote |
US prevalence projected from 2020 to 2050, AHI of 5 or more, adults aged 30 to 69, hypopnea scoring rule not stated (ResMed-funded simulation model)
“This study was funded by Resmed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obstructive sleep apnoea diagnosis was based age, sex, BMI, and AHI, a metric reflecting the number of apnoea and hypopnoea events per hour of sleep,22 with individuals considered to have obstructive sleep apnoea if their AHI was 5/h or higher.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By 2050, the prevalence of obstructive sleep apnoea (apnoea–hypopnoea index ≥5/h) is expected to show a relative increase of 34·7%, from 34·3% (95% uncertainty interval [UI] 34·0–34·4) to 46·2% (46·0–46·4), resulting in 76·6 million cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Males are projected to show a more moderate relative increase of 19·3%, from 45·6% (45·4–46·0) to 54·4% (54·2–54·7), reaching 45·9 million cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a disproportionate growth among females compared with males.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of AHI of 15 or more with AASM 2012 hypopnea rule, adults aged 40 to 85 in Lausanne, Switzerland (HypnoLaus)
“We used the 2012 criteria for our analysis (because they are the most recent and currently recommended criteria) and reported the average number of apnoea and hypopnoea events per h of sleep (the apnoea-hypopnoea index).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“1024 (48%) participants were men, with a median age of 57 years (IQR 49–68, range 40–85) and mean body-mass index (BMI) of 25·6 kg/m2 (SD 4·1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of moderate-to-severe sleep-disordered breathing (≥15 events per h) was 23·4% (95% CI 20·9–26·0) in women and 49·7% (46·6–52·8) in men.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of an apnea-hypopnea score of 5 or more, employed Wisconsin adults aged 30 to 60 (Wisconsin Sleep Cohort, polysomnography)
“A random sample of 602 employed men and women 30 to 60 years old were studied by overnight polysomnography to determine the frequency of episodes of apnea and hypopnea per hour of sleep (the apnea-hypopnea score).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated prevalence of sleep-disordered breathing, defined as an apnea-hypopnea score of 5 or higher, was 9 percent for women and 24 percent for men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We estimated that 2 percent of women and 4 percent of men in the middle-aged work force meet the minimal diagnostic criteria for the sleep apnea syndrome (an apnea-hypopnea score of 5 or higher and daytime hypersomnolence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Range of general-population prevalence across 24 studies, AHI of 5 or more and 15 or more (systematic review)
“Twenty-four studies out of 3807 found by systematically searching PubMed and Embase databases were included in this review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At ≥5 events/h apnea-hypopnea index (AHI), the overall population prevalence ranged from 9% to 38% and was higher in men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It increased with increasing age and, in some elderly groups, was as high as 90% in men and 78% in women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At ≥15 events/h AHI, the prevalence in the general adult population ranged from 6% to 17%, being as high as 49% in the advanced ages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence in clinical populations: bariatric surgery candidates and people with stroke or transient ischemic attack
“In some populations, the prevalence of OSA is substantially higher than this estimate, for example, in patients being evaluated for bariatric surgery (estimated range of 70% to 80%)11 or in patients who have had a transient ischemic attack or stroke (estimated range of 60% to 70%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Undiagnosed share of moderate to severe sleep apnea syndrome, employed adults in Wisconsin
Diagnosed and undiagnosed US adults, AHI over 5 (Frost & Sullivan report commissioned by the AASM)
Diagnosed prevalence in US insured adults and children with claims activity, 2013 to 2016 (nationwide claims, Jazz Pharmaceuticals-funded)
“Nationwide medical/prescription claims (Symphony Health) were analyzed to estimate the annual prevalence per 100,000 persons of narcolepsy and other sleep disorders (obstructive sleep apnea, idiopathic hypersomnia, rapid eye movement sleep behavior disorder, periodic limb movement disorder) and the frequency of diagnostic sleep testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obstructive sleep apnea prevalence increased 41% over the study period from 2,429 to 3,420 per 100,000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Jazz Pharmaceuticals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Documented sleep-related breathing disorders in Veterans Affairs outpatients, 2018
Natural history, survival, and mortality
Progression with weight gain: Wisconsin Sleep Cohort, AHI as apnea plus hypopnea events per hour of sleep
“Six hundred ninety randomly selected employed Wisconsin residents (mean age at baseline, 46 years; 56% male) who were evaluated twice at 4-year intervals for SDB.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Percentage change in the apnea-hypopnea index (AHI; apnea events + hypopnea events per hour of sleep) and odds of developing moderate-to-severe SDB (defined by an AHI > or =15 events per hour of sleep), with respect to change in weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to stable weight, a 10% weight gain predicted an approximate 32% (95% confidence interval [CI], 20%-45%) increase in the AHI. A 10% weight loss predicted a 26% (95% CI, 18%-34%) decrease in the AHI. A 10% increase in weight predicted a 6-fold (95% CI, 2.2-17.0) increase in the odds of developing moderate-to-severe SDB.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression and regression over 5 years: Sleep Heart Health Study, respiratory disturbance index
“A total of 2968 men and women (mean age, 62 years) participated in the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Men were more likely to have an increase in Respiratory Disturbance Index (RDI) with a given increase in weight than were women, and this was not explained by differences in starting weight, waist circumference, age, or ethnicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a linear regression analysis, both men and women had a greater increase in RDI with weight gain than a decrease in RDI with weight loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, SDB progressed over time, even in those with stable weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
All-cause and cardiovascular mortality: Wisconsin Sleep Cohort 18-year follow-up, hypopnea with 4% desaturation
“An 18-year mortality follow-up was conducted on the population-based Wisconsin Sleep Cohort sample (n = 1522), assessed at baseline for SDB with polysomnography, the clinical diagnostic standard.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Apnea was defined as cessation of airflow for ≥ 10 seconds and hypopnea was defined as a discernible reduction in breathing (sum of chest and abdominal excursions) with a reduction in oxyhemoglobin saturation of ≥ 4%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The adjusted hazard ratio (HR, 95% CI) for all-cause mortality with severe versus no SDB was 3.0 (1.4,6.3). After excluding persons who had used CPAP treatment (n = 126), the adjusted HR (95% CI) for all-cause mortality with severe versus no SDB was 3.8 (1.6,9.0); the adjusted HR (95% CI) for cardiovascular mortality was 5.2 (1.4,19.2). Results were unchanged after accounting for daytime sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation
“We prospectively examined whether sleep-disordered breathing was associated with an increased risk of death from any cause in 6,441 men and women participating in the Sleep Heart Health Study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The apnea–hypopnea index (AHI) was defined as the number of apneas and hypopneas, each associated with a 4% or greater decrease in oxygen saturation, per hour of sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average follow-up period for the cohort was 8.2 y during which 1,047 participants (587 men and 460 women) died. Compared to those without sleep-disordered breathing (AHI: <5 events/h), the fully adjusted hazard ratios for all-cause mortality in those with mild (AHI: 5.0–14.9 events/h), moderate (AHI: 15.0–29.9 events/h), and severe (AHI: ≥30.0 events/h) sleep-disordered breathing were 0.93 (95% CI: 0.80–1.08), 1.17 (95% CI: 0.97–1.42), and 1.46 (95% CI: 1.14–1.86), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stratified analyses by sex and age showed that the increased risk of death associated with severe sleep-disordered breathing was statistically significant in men aged 40–70 y (hazard ratio: 2.09; 95% CI: 1.31–3.33). Measures of sleep-related intermittent hypoxemia, but not sleep fragmentation, were independently associated with all-cause mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
All-cause mortality: Busselton Health Study, home-monitor respiratory disturbance index with 3% desaturation
“Residents of the Western Australian town of Busselton underwent investigation with a home sleep apnea monitoring device (MESAM IV). OSA was quantified via the respiratory disturbance index (RDI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Respiratory disturbances were defined as oxygen desaturations of ≥ 3% from the preceding baseline level that were accompanied by either a) an increased heart rate ≥ 10 beats/min and/or b) a burst of snoring associated with commencement and termination of the desaturation event (i.e., an audible apnea).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 380 participants, 18 had moderate-severe OSA (RDI ≥15/hr, 6 deaths) and 77 had mild OSA (RDI 5 to <15/hr, 5 deaths). Moderate-to-severe OSA was independently associated with greater risk of all-cause mortality (fully adjusted hazard ratio [HR] = 6.24, 95% CL 2.01, 19.39) than non-OSA (n = 285, 22 deaths). Mild OSA (RDI 5 to <15/hr) was not an independent risk factor for higher mortality (HR = 0.47, 95% CL 0.17, 1.29).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fatal and non-fatal cardiovascular events: untreated severe disease and CPAP-treated men in a sleep clinic cohort
“Participants were followed-up at least once per year for a mean of 10.1 years (SD 1.6) and CPAP compliance was checked with the built-in meter.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with untreated severe disease had a higher incidence of fatal cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 per 100 person-years) than did untreated patients with mild-moderate disease (0.55, p=0.02 and 0.89, p<0.0001), simple snorers (0.34, p=0.0006 and 0.58, p<0.0001), patients treated with CPAP (0.35, p=0.0008 and 0.64, p<0.0001), and healthy participants (0.3, p=0.0012 and 0.45, p<0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Multivariate analysis, adjusted for potential confounders, showed that untreated severe obstructive sleep apnoea-hypopnoea significantly increased the risk of fatal (odds ratio 2.87, 95%CI 1.17-7.51) and non-fatal (3.17, 1.12-7.51) cardiovascular events compared with healthy participants.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular mortality by hypoxic burden: MrOS and Sleep Heart Health Study
“The hypoxic burden was determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike the AHI, the hypoxic burden strongly predicted CVD mortality and all-cause mortality (only in MrOS). Individuals in the MrOS study with hypoxic burden in the highest two quintiles had hazard ratios of 1.81 [95% confidence interval (CI) 1.25–2.62] and 2.73 (95% CI 1.71–4.36), respectively. Similarly, the group in the SHHS with hypoxic burden in the highest quintile had a hazard ratio of 1.96 (95% CI 1.11–3.43).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term outcomes of untreated disease: systematic review of longitudinal studies
“Among 26 articles, ten evaluated the association of OSA with mortality, 9 with a composite CV outcome, 4 with stroke, 2 with diabetes and 1 with depression. Significant relationships between the apnea-hypopnea index (AHI) and outcomes of interest were reported in 18 studies: seven for all-cause mortality, six for composite CV events, three for stroke, one for diabetes and one for depression. The effect of AHI was attenuated by female gender, older age, absence of daytime sleepiness and higher body mass index.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Evidence exists in men for a relationship between OSA and all-cause mortality and a composite CV outcome. Associations between OSA and other outcomes remain uncertain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Upper airway collapse when anatomical collapsing forces exceed dilator muscle compensation
Endotype framework: four physiological traits that cause OSA
“In this study, we present a noninvasive method for measuring four important physiological traits causing OSA: 1) pharyngeal anatomy/collapsibility, 2) ventilatory control system gain (loop gain), 3) the ability of the upper airway to dilate/stiffen in response to an increase in ventilatory drive, and 4) arousal threshold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The measurements and model illustrate the multifactorial nature of OSA pathogenesis and how, in some individuals, small adjustments of one or another trait (which might be achievable with non-CPAP agents) could potentially treat OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endotype framework: distribution of anatomical and nonanatomical traits among patients with OSA
“A total of 36% of patients with OSA had minimal genioglossus muscle responsiveness during sleep, 37% had a low arousal threshold, and 36% had high loop gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 28% had multiple nonanatomic features.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One or more nonanatomic pathophysiologic traits are present in 69% of patients with OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study confirms that OSA is a heterogeneous disorder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endotype framework: impaired anatomy and the three nonanatomical phenotypes
“Indeed, impairment in pharyngeal anatomy can be modest and in many patients (∼20%), pharyngeal collapsibility asleep is not different to people without OSA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These include impairment in pharyngeal dilator muscle control and function during sleep, increased propensity for awakening during airway narrowing (low respiratory arousal threshold) and respiratory control instability (high loop gain).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Each phenotype is a potential therapeutic target.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endotype framework: estimating collapsibility and muscle compensation from diagnostic polysomnography
“Here we aimed to provide a means to quantify two key contributors to OSA—pharyngeal collapsibility and compensatory muscle responsiveness—that is applicable to diagnostic polysomnography.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Phenotypes of pharyngeal dysfunction in OSA are evident from spontaneous changes in ventilation and ventilatory drive during sleep, enabling noninvasive phenotyping in the clinic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: noradrenergic withdrawal in NREM sleep and muscarinic inhibition in REM sleep
“Some preclinical works identified the main cause of sleep-related hypotonia of the pharyngeal muscles to be the central reduction of norepinephrine from wakefulness to sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, an inhibitory effect of acetylcholine through muscarinic receptors was found to be responsible for the REM-related hypotonia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two key contributors are now thought to be important: sleep-related withdrawal of endogenous noradrenergic drive is a major cause of genioglossus hypotonia, particularly during non-REM (NREM) sleep (16), and active muscarinic inhibition mediates pharyngeal hypotonia, particularly during REM (17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: muscarinic and GIRK channel inhibition at the hypoglossal motor pool in REM sleep (rat study)
“Here we show that muscarinic receptor antagonism at the hypoglossal motor pool prevents the inhibition of genioglossus activity throughout REM sleep; likewise, with G-protein-coupled inwardly rectifying potassium (GIRK) channel blockade.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This mechanism is the major cause of REM sleep inhibition at a pharyngeal motor pool critical for effective breathing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: genioglossus motor unit activity during REM sleep in humans
“Overall these data show diminished genioglossus activity during REM (particularly phasic REM) as evidenced by fewer SMUs being active, reduced discharge frequencies, and shorter firing durations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neither the source of this cholinergic input nor the nature of interactions between cholinergic, noradrenergic, and other excitatory neurochemicals is understood.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal dilator muscle control: hypoglossal motor nucleus mechanisms targeted by AD109 (review; one author is an Apnimed employee)
“While anatomical vulnerability contributes to airway instability, a key determinant of OSA pathophysiology is the sleep-related reduction in upper airway neuromuscular activity that occurs at the wake–sleep transition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonanatomical causes contribute to OSA in approximately 70% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This endogenous noradrenergic excitation at the HMN is present in wakefulness, reduced in non-REM (NREM) sleep, and further reduced in REM sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upper airway dilator muscle activity decreases during sleep due to withdrawal of excitatory drive, including noradrenergic input, in rapid eye movement (REM) and non-REM (NREM) sleep, and recruitment of inhibitory muscarinic–GIRK (G-protein–coupled inwardly rectifying potassium) mechanisms in REM sleep at upper airway motor nuclei.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AD109 combines norepinephrine reuptake inhibition (atomoxetine) to restore excitatory drive and antimuscarinic activity (aroxybutynin) to reduce inhibition, thereby stabilizing upper airway muscle tone and improving airway patency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“R.L.H.’s laboratory received an unrestricted grant in September 2024 from Apnimed, Inc. to support future research in obstructive sleep apnea (OSA) pharmacotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“L.T.-M. is an Apnimed employee and is co-inventor of intellectual property for pharmacological therapy of OSA via the Brigham and Women’s Hospital.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Diagnostic criteria: ICSD-3 definition as stated in the AASM diagnostic testing guideline
“The third edition of the International Classification of Sleep Disorders (ICSD-3) defines OSA as a PSG-determined obstructive respiratory disturbance index (RDI) ≥ 5 events/h associated with the typical symptoms of OSA (e.g., unrefreshing sleep, daytime sleepiness, fatigue or insomnia, awakening with a gasping or choking sensation, loud snoring, or witnessed apneas), or an obstructive RDI ≥ 15 events/h (even in the absence of symptoms).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to apneas and hypopneas that are included in the AHI, the RDI includes respiratory effort-related arousals (RERAs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnostic testing: AASM 2017 guideline recommendations on polysomnography and home sleep apnea testing
“Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. Polysomnography is the standard diagnostic test for the diagnosis of OSA in adult patients in whom there is a concern for OSA based on a comprehensive sleep evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that clinical tools, questionnaires and prediction algorithms not be used to diagnose OSA in adults, in the absence of polysomnography or home sleep apnea testing. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that polysomnography, or home sleep apnea testing with a technically adequate device, be used for the diagnosis of OSA in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that if a single home sleep apnea test is negative, inconclusive, or technically inadequate, polysomnography be performed for the diagnosis of OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend that polysomnography, rather than home sleep apnea testing, be used for the diagnosis of OSA in patients with significant cardiorespiratory disease, potential respiratory muscle weakness due to neuromuscular condition, awake hypoventilation or suspicion of sleep related hypoventilation, chronic opioid medication use, history of stroke or severe insomnia. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that, if clinically appropriate, a split-night diagnostic protocol, rather than a full-night diagnostic protocol for polysomnography be used for the diagnosis of OSA. (WEAK)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that when the initial polysomnogram is negative and clinical suspicion for OSA remains, a second polysomnogram be considered for the diagnosis of OSA. (WEAK)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home sleep apnea testing: candidate criteria, device requirements, and respiratory event index
“An increased risk of moderate to severe OSA is indicated by the presence of excessive daytime sleepiness and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping or choking, or diagnosed hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography, and oximetry; or else PAT with oximetry and actigraphy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A technically adequate diagnostic test includes a minimum of 4 hours of technically adequate oximetry and flow data, obtained during a recording attempt that encompasses the habitual sleep period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Measurement error is inevitable in HSAT, compared against PSG, as standard sleep staging channels are not typically monitored in HSAT (e.g., EEG, EOG and EMG monitoring are not typically performed), which results in use of the recording time rather than sleep time to define the denominator of the respiratory event index (REI; the term used to represent the frequency of apneas and hypopneas derived from HSAT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HSAT devices that use conventional sensors are unable to detect hypopneas only associated with cortical arousals, which are included in the recommended AHI scoring rule in the AASM Scoring Manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening and diagnostic testing: VA/DoD 2025 Recommendations 1 to 4
Screening: STOP questionnaire scoring in the VA/DoD guideline
Severity thresholds: VA/DoD 2025 guideline, AHI on HSAT and severity for treatment selection
Severity thresholds: AASM 2009 adult OSA clinical guideline
“The diagnosis of OSA is confirmed if the number of obstructive events (apneas, hypopneas + respiratory event related arousals) on PSG is greater than 15 events/hr or greater than 5/hour in a patient who reports any of the following: unintentional sleep episodes during wakefulness; daytime sleepiness; unrefreshing sleep; fatigue; insomnia; waking up breath holding, gasping, or choking; or the bed partner describing loud snoring, breathing interruptions, or both during the patient's sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OSA severity is defined as mild for RDI ≥ 5 and < 15, moderate for RDI ≥ 15 and ≤ 30, and severe for RDI > 30/hr (Consensus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity thresholds: 1999 AASM task force grades and their consensus basis
“They also recommended severity criteria based on degree of sleepiness and frequency of respiratory events, with the following severity grades based on the number of obstructive breathing events per hour:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mild: 5 to 15 events per hour” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate: >15 to 30 events per hour” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Severe: greater than 30 events per hour” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It should be noted that these recommendations were based on expert consensus, with an acknowledgment that the data on which to base these event definitions and severity measures were limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scoring rules: AASM 2012 recommended hypopnea rule with 3% desaturation or arousal, and 4% rule for reimbursement
“Score a respiratory event as a hypopnea if all of the following are met:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The peak signal excursions drop by ≥ 30% of pre-event baseline using nasal pressure (diagnostic study), PAP device flow (titration study), or an alternative hypopnea sensor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The duration of the ≥ 30% drop in signal excursions is ≥ 10 seconds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is ≥ 3% oxygen desaturation from pre-event baseline or the event is associated with an arousal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Note: If necessary, the number of hypopneas using a definition requiring ≥ 30% drop in flow for ≥ 10 seconds that is associated with ≥ 4% desaturation may additionally be reported to qualify a patient for PAP reimbursement (e.g., Medicaid or Medicare patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For Medicaid and Medicare patients the use of a hypopnea definition based on a 30% drop in flow and 4% or greater desaturation will need to be used to ensure reimbursement until reimbursement policies are changed to reflect the new hypopnea definition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scoring rules: AASM 2012 adult apnea rule
“Score a respiratory event in adults as an apnea if both of the following are met:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is a drop in the peak signal excursion by ≥ 90% of pre-event baseline using an oronasal thermal sensor (diagnostic study), positive airway pressure device flow (titration study), or an alternative apnea sensor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The duration of the ≥ 90% drop in sensor signal is ≥ 10 seconds.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of the hypopnea definition on the AHI: 3% versus 4% desaturation
“Recognizing the apparent equivalence of hypopnea definitions requiring ≥ 3% or ≥ 4% desaturation, the task force has recommended adoption of the 3% criterion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with median AHI in a general community sample being almost twice as great using a 3% as a 4% criterion” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, thresholds for identification of the presence and severity of OSA, and for inferring health-related consequences of OSA, must be calibrated to the hypopnea definition employed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of the hypopnea definition on the AHI: three AASM definitions in clinical polysomnography
“For AHIRec, hypopneas were required to have ≥ 30% airflow reduction and ≥ 4% desaturation; and for AHIAlt, hypopneas were required to have ≥ 50% airflow reduction and ≥ 3% desaturation or arousal. The median AHIRec was approximately 30% of the median AHIChicago, whereas the median AHIAlt was approximately 60% of the AHIChicago, with large, AHI-dependent, patient-specific differences observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Failure to adjust cut-points for the new criteria would result in approximately 40% of patients previously classified as positive for OSA using AHIChicago being negative using AHIRec and 25% being negative using AHIAlt.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study demonstrates that using different published standard hypopnea definitions leads to marked differences in AHI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare coverage thresholds: CPAP national coverage determination, AHI or RDI with 4% desaturation hypopnea rule
Medicare coverage of sleep tests: national coverage determination for sleep testing
Sleepiness assessment: Epworth Sleepiness Scale
“This is a simple, self-administered questionnaire which is shown to provide a measurement of the subject's general level of daytime sleepiness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“They rated the chances that they would doze off or fall asleep when in eight different situations commonly encountered in daily life.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with obstructive sleep apnea syndrome ESS scores were significantly correlated with the respiratory disturbance index and the minimum SaO2 recorded overnight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Metrics beyond the AHI: hypoxic burden and limits of the AHI
“Apnoea–hypopnoea index (AHI), the universal clinical metric of sleep apnoea severity, poorly predicts the adverse outcomes of sleep apnoea, potentially because the AHI, a frequency measure, does not adequately capture disease burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The hypoxic burden was determined by measuring the respiratory event-associated area under the desaturation curve from pre-event baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect. We further review the potential value of alternative metrics including hypoxic burden, arousal intensity, odds ratio product, and cardiopulmonary coupling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Nocturnal symptoms: snoring, witnessed apneas, gasping or choking, nocturia, and morning headaches
“A comprehensive sleep history in a patient suspected of OSA should include an evaluation for snoring, witnessed apneas, gasping/choking episodes, excessive sleepiness not explained by other factors, including assessment of sleepiness severity by the Epworth Sleepiness Scale,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“total sleep amount, nocturia, morning headaches, sleep fragmentation/sleep maintenance insomnia, and decreased concentration and memory (Consensus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Daytime symptoms: unrefreshing sleep, fatigue, and sleepiness
Daytime symptoms: sleepiness across respiratory disturbance index levels in the Sleep Heart Health Study
“Sleep-disordered breathing was quantified by the respiratory disturbance index (RDI), defined as the number of apneas plus hypopneas per hour of sleep, measured during in-home polysomnography.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When RDI was categorized into four groups (< 5, 5 to < 15, 15 to < 30, >/= 30), a significantly progressive increase in mean ESS score was seen across all four levels of SDB, from 7.2 (4.3) in subjects with RDI < 5 to 9.3 (4.9) in subjects with RDI >/= 30 (p < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of subjects with excessive sleepiness, defined as an ESS score >/= 11, increased from 21% in subjects with RDI < 5 to 35% in those with RDI >/= 30 (p < 0. 001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neurocognitive and psychosocial symptoms: vigilance, concentration, cognition, and quality of life
“They may suffer from impairments in vigilance, concentration, cognitive function, social interactions and quality of life (QOL). These declines in daytime function can translate into higher rates of job-related and motor vehicle accidents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insomnia symptoms: comorbid insomnia and obstructive sleep apnea
Physical signs: obesity, neck circumference, and upper airway anatomy
“Particular attention should be paid to the presence of obesity, signs of upper airway narrowing, or the presence of other disorders that can contribute to the development of OSA or to the consequences of OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“body mass index (BMI) ≥ 30 kg/m2, a Modified Mallampati score of 3 or 4” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the presence of retrognathia, lateral peritonsillar narrowing, macroglossia, tonsillar hypertrophy, elongated/enlarged uvula, high arched/narrow hard palate, nasal abnormalities (polyps, deviation, valve abnormalities, turbinate hypertrophy) and/or overjet (Consensus).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic presentation: conditions that place patients at high risk of OSA
Symptom subtypes: disturbed sleep, minimally symptomatic, excessively sleepy, and moderately sleepy in the Sleep Heart Health Study
“Data from 1,207 patients with OSA (apnea–hypopnea index ≥ 15 events/h) were used to evaluate the existence of symptom subtypes using latent class analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Four symptom subtypes were identified (disturbed sleep [12.2%], minimally symptomatic [32.6%], excessively sleepy [16.7%], and moderately sleepy [38.5%]), similar to prior studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimally symptomatic presentation: undiagnosed and minimally sleepy populations
“While most of these cases are undiagnosed, it is likely that most are asymptomatic or minimally symptomatic, and it remains uncertain whether these individuals have a disorder that requires therapeutic intervention” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex differences in symptoms: matched men and women across AHI strata
“Study participants were classified as having no SDB (apnea-hypopnea index [AHI] <5 events/h), mild SDB (5.0-14.9 events/h), or moderate-to-severe SDB (≥15 events/h). Within each stratum, men and women were matched 1:1 on age, race, body mass index, and AHI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“whereas women had more insomnia symptoms and lower physical and mental quality-of-life scores (both p = 0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comparable levels of SDB severity carry different physiologic and symptomatic consequences in men and women, indicating that assessment should extend beyond AHI alone to include sleep disruption, symptom profile, and functional impact.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Hypertension: incident hypertension in the Wisconsin Sleep Cohort by baseline AHI
“Participants were assessed overnight by 18-channel polysomnography for sleep-disordered breathing, as defined by the apnea-hypopnea index (the number of episodes of apnea and hypopnea per hour of sleep).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to the reference category of an apnea-hypopnea index of 0 events per hour at base line, the odds ratios for the presence of hypertension at follow-up were 1.42 (95 percent confidence interval, 1.13 to 1.78) with an apnea-hypopnea index of 0.1 to 4.9 events per hour at base line as compared with none, 2.03 (95 percent confidence interval, 1.29 to 3.17) with an apnea-hypopnea index of 5.0 to 14.9 events per hour, and 2.89 (95 percent confidence interval, 1.46 to 5.64) with an apnea-hypopnea index of 15.0 or more events per hour.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We found a dose-response association between sleep-disordered breathing at base line and the presence of hypertension four years later that was independent of known confounding factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hypertension: cross-sectional association in the Sleep Heart Health Study, hypopnea with 4% desaturation
“Apnea-hypopnea index (AHI, the average number of apneas plus hypopneas per hour of sleep, with apnea defined as a cessation of airflow and hypopnea defined as a > or = 30% reduction in airflow or thoracoabdominal excursion both of which are accompanied by a > or = 4% drop in oxyhemoglobin saturation) [corrected], obtained by unattended home polysomnography.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for demographics and anthropometric variables (including BMI, neck circumference, and waist-to-hip ratio), as well as for alcohol intake and smoking, the odds ratio for hypertension, comparing the highest category of AHI (> or = 30 per hour) with the lowest category (< 1.5 per hour), was 1.37 (95% confidence interval [CI], 1.03-1.83; P for trend = .005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: prevalence of OSA in cardiovascular conditions, American Heart Association statement
“OSA prevalence is as high as 40% to 80% in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend screening for OSA in patients with resistant/poorly controlled hypertension, pulmonary hypertension, and recurrent atrial fibrillation after either cardioversion or ablation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Coronary heart disease and heart failure: Sleep Heart Health Study, apneas and hypopneas with 4% desaturation
“where both apneas and hypopneas required an associated 4% or greater oxyhemoglobin desaturation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A prospective, longitudinal epidemiologic study of 1927 men and 2495 women aged ≥ 40 years and free of coronary heart disease and heart failure at the time of baseline polysomnography were followed for a median of 8.7 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among men age 40–70 years, those with AHI ≥30 were 68% more likely to develop coronary heart disease than those with AHI <5. OSA predicted incident heart failure in men but not in women (adjusted hazard ratio 1.13 [95% CI 1.02, 1.26] per 10-unit increase in AHI). Men with AHI ≥30 were 58% more likely to develop heart failure than those with AHI <5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular disease: incident events by symptom subtype in the Sleep Heart Health Study
“Symptom subtype was also associated with incident cardiovascular disease (P < 0.001), coronary heart disease (P = 0.015), and heart failure (P = 0.018), with the excessively sleepy again demonstrating increased risk (hazard ratios, 1.7–2.4) compared with other subtypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ischemic stroke: Sleep Heart Health Study, obstructive apnea-hypopnea index
“A total of 5,422 participants without a history of stroke at the baseline examination and untreated for sleep apnea were followed for a median of 8.7 years. One hundred ninety-three ischemic strokes were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Men in the highest OAHI quartile (>19) had an adjusted hazard ratio of 2.86 (95% confidence interval, 1.1–7.4). In the mild to moderate range (OAHI, 5–25), each one-unit increase in OAHI in men was estimated to increase stroke risk by 6% (95% confidence interval, 2–10%). In women, stroke was not significantly associated with OAHI quartiles, but increased risk was observed at an OAHI greater than 25.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atrial fibrillation and other arrhythmias: Sleep Heart Health Study, respiratory disturbance index of 30 or more
“(1) 228 subjects with sleep-disordered breathing (respiratory disturbance index ⩾ 30) and (2) 338 subjects without sleep-disordered breathing (respiratory disturbance index < 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“4.8 versus 0.9% (p = 0.003) for atrial fibrillation; 5.3 versus 1.2% (p = 0.004) for nonsustained ventricular tachycardia; 25.0 versus 14.5% (p = 0.002) for complex ventricular ectopy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“individuals with sleep-disordered breathing had four times the odds of atrial fibrillation (odds ratio [OR], 4.02; 95% confidence interval [CI], 1.03–15.74), three times the odds of nonsustained ventricular tachycardia (OR, 3.40; 95% CI, 1.03–11.20), and almost twice the odds of complex ventricular ectopy (OR, 1.74; 95% CI, 1.11–2.74).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atrial fibrillation: incident hospitalization in a Western Australian sleep clinic cohort
“Study case subjects (6,841) were predominantly middle aged (48.3 ± 12.5 years old) and men (77%), and 455 developed AF during a median 11.9 years of follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After multivariable adjustment, independent predictors of incident AF were an apnea/hypopnea index (AHI) > 5/h (hazard ratio [HR], 1.55; 95% CI, 1.21-2.00), log (AHI + 1) (HR, 1.15; 95% CI, 1.06-1.26), and log (time with oxygen saturation < 90% + 1) (HR, 1.12; 95% CI, 1.06-1.19).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Type 2 diabetes: Wisconsin Sleep Cohort, hypopnea with 4% desaturation
“A total of 14.7% of subjects with an apnea–hypopnea index (AHI) of 15 or more had a diagnosis of diabetes compared with 2.8% of subjects with an AHI of less than 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The odds ratio for developing diabetes mellitus within 4 yr with an AHI of 15 or more compared with an AHI of less than 5 was 1.62 (95% confidence interval, 0.67–3.65; p = 0.24) when adjusting for age, sex, and body habitus.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although all hypopnea events were marked by oxyhemoglobin desaturation of 4% or greater” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type 2 diabetes: meta-analysis of prospective cohort studies
“This meta-analysis of six prospective cohort studies including a total of 5953 participants, with follow-up periods of 2.7-16 years, and 332 incident cases of type 2 diabetes, showed that moderate-severe OSA was associated with a greater risk of diabetes (RR 1.63; 95% confidence interval (CI): 1.09-2.45), as compared with the absence of OSA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For subjects with mild OSA, as compared with those without OSA, the pooled RR of developing type 2 diabetes was 1.22 (95% CI: 0.91-1.63).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Motor vehicle crashes: systematic review and meta-analysis of crash risk
“Individuals with OSA are clearly at increased risk for crash. The mean crash-rate ratio associated with OSA is likely to fall within the range of 1.21 to 4.89. Characteristics that may predict crash in drivers with OSA include BMI, apnea plus hypopnea index, oxygen saturation, and possibly daytime sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive impairment: mild cognitive impairment or dementia in older women, AHI of 15 or more
“Sleep disordered breathing was defined as an apnea-hypopnea index of 15 or more events per hour of sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with the 193 women without sleep disordered breathing, the 105 women (35.2%) with SDB were more likely to develop MCI/dementia (n=60 (31.1%) vs n=47 (44.8%)) even after multivariate adjustment (adjusted OR=1.85, 95% CI 1.11-3.08).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive impairment: meta-analysis of population-based studies
“Pooled analysis of the 6 prospective studies indicated that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to develop cognitive impairment, with no evidence of publication bias but significant heterogeneity between studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sleep-disordered breathing was not associated with global cognition or memory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cognitive decline: untreated and CPAP-treated older adults with Medicare claims for OSA
“We analyzed 777 participants from the 2011 National Health and Aging Trends Study (NHATS) with linked Medicare claims, with one or more claims for OSA and no baseline cognitive impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Untreated participants experienced a 69% faster decline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Obstructive sleep apnea
Humanistic burden and health-related quality of life
SF-36 quality of life by sleep-disordered breathing severity in the Sleep Heart Health Study
“Participants (n=5,816; mean age=63 years; 52.5% women) were enrolled in the nation-wide population-based Sleep Heart Health Study (SHHS) implemented to investigate sleep-disordered breathing as a risk factor in the development of cardiovascular disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Vitality was the sole SF-36 scale to have a linear association with the clinical categories of SDB (mild, moderate, severe SDB). However, individuals with severe SDB indicated significantly poorer QoL on several SF-36 scales.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings suggest 1) mild to moderate SDB is associated with reduced vitality, while severe SDB is more broadly associated with poorer QoL, 2) subjective sleep symptoms are comprehensively associated with poorer QoL, and 3) SF-36 mean score profiles for SDB and sleep symptoms are equivalent to other chronic diseases in the U.S. general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life, utility, and work productivity with and without excessive sleepiness in the US National Health and Wellness Survey
“Respondents self-reporting an OSA diagnosis were categorized as having ES (Epworth Sleepiness Scale [ESS] score ≥ 11) or not having ES (ESS score < 11). Comorbidities, health-related quality of life (HRQoL), and productivity were examined in three groups: OSA with ES (n = 731), OSA without ES (n = 1,452), and non-OSA controls (n = 86,961).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After controlling for covariates, the OSA with ES group had significantly lower (worse) scores for mental component score (41.81 versus 45.65 versus 47.81), physical component score (46.62 versus 48.68 versus 51.36), and SF-6D (0.65 versus 0.69 versus 0.73) compared with OSA without ES and non-OSA controls (all P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The OSA with ES group had significantly higher (greater burden) mean rates of presenteeism (25.98% impairment versus 19.24% versus 14.75%), work impairment (29.41% versus 21.82% versus 16.85%), and activity impairment (31.09% versus 25.46% versus 19.93%) compared with OSA without ES and non-OSA controls (all P < .01) after controlling for covariates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health state utilities by AHI severity in adults with obstructive sleep apnea and obesity, time trade-off study
“Participants with OSA and obesity (BMI ≥ 30) in the UK and US valued health state vignettes in time trade-off interviews.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Vignettes described four levels of OSA severity defined by apnea-hypopnea index: remission (<5), mild (5-14.9), moderate (15-29.9), and severe (≥30).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 208 participants (UK = 105; US = 103) completed interviews (50.0% male; mean age = 53.6y). Mean (SD) utilities ranged from 0.93 (0.08) for mild OSA to 0.85 (0.15) for severe OSA when considering health states with the option to use non-pharmacologic treatment. When participants imagined living with the symptoms of OSA without the non-pharmacologic treatment option, mean utilities ranged from 0.89 (0.13) for mild OSA to 0.68 (0.27) for severe OSA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bed partner effects: sleep, daytime functioning, and relationship quality
“The majority of studies found untreated OSA to have a negative impact on partners' objective and subjective sleep and daytime functioning, in particular mood, quality of life, and relationship quality. Improvements in partner-assessed sleep quality were reported for CPAP, OA, and surgery. Conflicting results were reported for partners' mood, quality of life, daytime sleepiness, and relationship quality. Perceived partner support was associated with greater CPAP use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For some couples, patients' snoring and its interference with partners' sleep lead to sleeping in separate rooms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bed partner effects: quality of life of bed partners before and after patient CPAP treatment
“Of the 54 subjects who completed the study, the mean (+/- SD) apnea-hypopnea index was 48.4 +/- 33.3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For the bed partners, the mean ESS decreased from 7.4 +/- 6.1 to 5.8 +/- 4.7 (p = 0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OSA results in impaired QOL in both the patients and their bed partners. Treatment with CPAP improves QOL, as measured by the SF-36 and the SAQLI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Estimated U.S. societal cost of undiagnosed obstructive sleep apnea in 2015
Workplace productivity loss attributed to obstructive sleep apnoea syndrome in the USA
“This study estimates the prevalence and workplace productivity burden of obstructive sleep apnoea (OSA) syndrome in the UK and USA, using self-reported breathing pauses and excessive daytime sleepiness as a proxy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual productivity losses were estimated at US$180.2 billion in the USA and £4.22 billion in the UK. In the UK and USA, individual-level productivity losses exceeded the cost of continuous positive airway pressure (CPAP) treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries: health care use and costs in the year before obstructive sleep apnea treatment
“The final sample (n = 287,191) included 10,317 beneficiaries with OSA and 276,874 control patients. In fully adjusted models, during the year prior to OSA diagnosis and relative to matched control patients, beneficiaries with OSA demonstrated increased HCU and higher mean total annual costs ($19,566, 95% confidence interval [CI] $13,239, $25,894) as well as higher mean annual costs across all individual points of service.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inpatient care was associated with the highest incremental costs (ie, greater than control patients; $15,482, 95% CI $8,521, $22,443) and prescriptions were associated with the lowest incremental costs (ie, greater than control patients; $431, 95% CI $339, $522).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medical costs in the year before diagnosis of sleep apnea, single health plan
“Among cases, mean annual medical cost prior to diagnosis was $2720 versus $1384 for age and gender matched controls (p<0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using available data on the prevalence of undiagnosed moderate to severe sleep apnea in middle-aged adults, we estimate that untreated sleep apnea may cause $3.4 billion in additional medical costs in the U.S.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Positive airway pressure adherence and health care use and costs in obstructive sleep apnea with obesity, ResMed-funded claims analysis
“Among 173,691 patients, 35.2% were adherent, 39.1% intermediately adherent, and 25.7% nonadherent. After applying inverse probability of treatment weighting (IPTW), in year 1 post-index, adherent patients had significantly fewer ER visits and hospitalizations (0.55 ± 1.77 and 0.10 ± 0.44) compared to nonadherent patients (0.69 ± 1.78 and 0.14 ± 0.56; P < 0.001), and significantly lower total healthcare costs (11,332 ± 21,160 vs 11,927 ± 20,212; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by Resmed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Positive airway pressure adherence and health care use in comorbid insomnia and obstructive sleep apnea, ResMed-funded claims analysis
“From a sample of 27,071 patients with COMISA (average age, 53.6 years; 53% female), 72% were at least intermediately adherent to PAP over 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When viewed in the context of patients with OSA without insomnia, patients with COMISA showed lower PAP use and higher rates of resource use both before and after the index date, but showed similar relative reductions in ER visits and hospitalizations with PAP adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was funded by ResMed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CPAP adherence and inpatient use in Medicare beneficiaries with cardiovascular disease
CPAP adherence and 30-day readmission in Medicare beneficiaries with cardiovascular disease
“Among 1,301 beneficiaries meeting study criteria, the 30-day readmission rate was 10.2%. In adjusted models and compared to patients with low CPAP adherence, those with high adherence had lower odds of 30-day readmission (odds ratio 0.41; 95% confidence interval 0.24–0.70).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CPAP termination and permanent work disability in the French national claims database
“The analysis included 174,270 individuals (median age, 52.0 yr [interquartile range, 44.0–57.0 yr]; 67.5% male). The 1-year CPAP therapy termination rate was 22.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In an adjusted multivariable Cox model, CPAP termination was associated with an increased risk of permanent work disability (hazard ratio, 1.21; 95% confidence interval [CI], 1.04–1.41; P = 0.01), primarily in the subgroup aged >55 years (hazard ratio, 1.41; 95% CI, 1.06–1.87; P = 0.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal cost-of-illness estimate for Italy from a systematic review
“Twenty-six clinical (e.g., diabetes) and non-clinical (e.g., car accidents) conditions were found to be significantly influenced by OSA, contributing to an economic burden ranging from €10.7 to €32.0 billion/year in Italy. The cost of impaired quality of life due to OSA undertreatment is between €2.8 and €9.0 billion/year. These costs are substantially higher than those currently borne to diagnose and treat OSA (€234 million/year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Obstructive sleep apnea on families
Not applicable.
Economic impact of diagnostic testing
Medicare diagnostic testing requirement for CPAP coverage
Sleep test documentation required for prior authorization of tirzepatide for obstructive sleep apnea
Share of U.S. diagnosis and treatment spending attributed to testing and office visits, 2015
Home versus laboratory diagnostic pathway: payer and provider costs in the HomePAP trial
“From the payer perspective, per subject costs for the laboratory-based pathway were $1,840 (95% confidence interval [CI] $1,660, $2,015) compared to $1,575 (95% CI $1,439, $1,716) for the home-based pathway under the base case. Costs were $264 (95% CI $39, $496, P = 0.02) in favor of the home arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For payers, a home-based diagnostic pathway for obstructive sleep apnea with robust patient support incurs fewer costs than a laboratory-based pathway. For providers, costs are comparable if not higher, resulting in a negative operating margin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home versus laboratory diagnostic pathway: clinical outcomes in the HomePAP trial
Home versus laboratory diagnostic pathway: functional outcome in veterans
“Functional outcome and treatment adherence in patients evaluated according to a home testing algorithm is not clinically inferior to that in patients receiving standard in-laboratory polysomnography.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of diagnostic strategies with CPAP in a U.S. lifetime model
“Over the lifetime horizon in a population with 50% prevalence of OSA, full-night polysomnography in conjunction with CPAP therapy is the most economically efficient strategy at any willingness-to-pay greater than $17,131 per-QALY gained because it dominates all other strategies in comparative analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-utility of polysomnography, home testing, and empirical CPAP
Systematic review of economic evaluations of diagnostic strategies
“Twenty-nine studies were included. Fifteen studies included an economic evaluation alongside a clinical trial and 14 studies were model-based economic analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Substantial methodological heterogeneity was identified across studies, including variation in diagnostic thresholds and scoring criteria used, model structures and assumptions regarding treatment adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Positive airway pressure therapy
VA/DoD guideline: evidence cutoff date for the 2025 recommendations
VA/DoD guideline: mandibular advancement devices, PAP, or surgical referral (strong for)
VA/DoD guideline algorithm: PAP as first-line therapy for severe OSA
VA/DoD guideline: auto-titrating over fixed CPAP at initiation (weak for)
VA/DoD guideline: educational, behavioral, and supportive interventions to improve PAP usage (weak for)
VA/DoD guideline: PAP effects on symptoms, cardiovascular outcomes, and side effects
AASM guideline: PAP for excessive sleepiness (strong), impaired sleep-related quality of life (conditional), and comorbid hypertension (conditional)
“Recommendation 1: We recommend that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with excessive sleepiness. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TF identified 38 randomized controlled trials (RCTs) that assessed the efficacy of PAP to reduce excessive sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 2: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with impaired sleep-related quality of life. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 3: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with comorbid hypertension. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This clinical practice guideline reflects the state of knowledge at the time of publication and will be reviewed and updated as new information becomes available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASM guideline: PAP initiation, modality, and adherence interventions
“Recommendation 4: We recommend positive airway pressure therapy be initiated using either APAP at home or in-laboratory PAP titration in adults with OSA and no significant comorbidities. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 5: We recommend that clinicians use either APAP or CPAP for ongoing treatment of OSA in adults. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 6: We suggest that clinicians use CPAP or APAP over BPAP in the routine treatment of OSA in adults. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 7: We recommend that educational interventions be given prior to initiation of PAP therapy in adults with OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 9: We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASM guideline: no recommendation on PAP to reduce cardiovascular events in non-sleepy adults
“There is insufficient and inconclusive evidence to either recommend or withhold PAP to treat non-sleepy adults with OSA as a means to reduce cardiovascular events or mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses of observational studies suggested a reduction in CV events and mortality with PAP therapy. In contrast, meta-analyses of randomized controlled trials demonstrated no clinically significant improvements in CV events or mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ACP guideline: CPAP as initial therapy (strong recommendation, moderate-quality evidence)
“This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RECOMMENDATION 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SAVE: CPAP and cardiovascular events in OSA with established cardiovascular disease, OSA defined by a 4% oxygen desaturation index of at least 12
ISAACC: CPAP and cardiovascular events after acute coronary syndrome in non-sleepy participants
“The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RICCADSA: CPAP in coronary artery disease with non-sleepy OSA, AHI of at least 15 per hour, hypopnea scoring rule not stated in the abstract
“Consecutive patients with newly revascularized CAD and OSA (apnea-hypopnea index ≥15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were randomized to auto-titrating CPAP (n = 122) or no positive airway pressure (n = 122).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of the primary endpoint did not differ significantly in patients who did versus did not receive CPAP (18.1% vs. 22.1%; hazard ratio, 0.80; 95% confidence interval, 0.46-1.41; P = 0.449).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted on-treatment analysis showed a significant cardiovascular risk reduction in those who used CPAP for ≥4 versus <4 hours per night or did not receive treatment (hazard ratio, 0.29; 95% confidence interval, 0.10-0.86; P = 0.026).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CPAP and incident hypertension or cardiovascular events in non-sleepy OSA, AHI of at least 20 per hour, hypopnea scoring rule not stated in the abstract
“Between May 2004 and May 2006, 725 consecutive patients were enrolled who had an apnea-hypopnea index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from 0-24, with values <10 suggesting no daytime sleepiness).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence density ratio was 0.83 (95% CI, 0.63-1.1; P = .20).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual care did not result in a statistically significant reduction in the incidence of hypertension or cardiovascular events. However, the study may have had limited power to detect a significant difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Individual participant data meta-analysis of SAVE, ISAACC, and RICCADSA: intention-to-treat and adherent CPAP use
“The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 4186 individual participants were evaluated (82.1% men; mean [SD] body mass index, 28.9 [4.5]; mean [SD] age, 61.2 [8.7] years; mean [SD] apnea-hypopnea index, 31.2 [17] events per hour; 71% with hypertension; 50.1% receiving CPAP [mean {SD} adherence, 3.1 {2.4} hours per day]; 49.9% not receiving CPAP [usual care], mean [SD] follow-up, 3.25 [1.8] years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of randomized trials: PAP and cardiovascular events or death in sleep apnea
“The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean or median adherence to the intervention ranged between 1.4 hours per day and 6.6 hours per day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence: nonadherence range across studies using a 4-hour nightly threshold
Adherence: CPAP nonadherence pooled across 20 years of trials, relative to a 7-hour night
“The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence: 90-day adherence by the Medicare definition in a device manufacturer’s cloud database
“We assessed de-identified data from a large cloud database of positive airway pressure (PAP) users to examine adherence to therapy during the period 1-Oct-2014 to 31-Oct-2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All Air10 platform PAP devices (ResMed Inc., San Diego, USA) have an on-board mobile communications chip which connects to the secure cloud infrastructure automatically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ResMed Corp, USA funded the study and their employees (JA, AB, CMN) contributed to the design and conduct of the study, analysis, and interpretation of the data and preparation of the manuscript for publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome was adherence, which was defined using the US Center for Medicare and Medicaid Services (CMS) definition (≥4 hours’ PAP use on 70% of nights in a consecutive 30-day period in the first 90 days of therapy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed 90-day PAP adherence rate using the CMS definition was 75%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior studies suggest that up to 24% of patients may not fulfill their PAP prescription [14] and a proportion of patients may not even turn on their PAP machine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Termination: CPAP termination at 1, 2, and 3 years in French national claims
“Therapy termination was defined as cessation of CPAP reimbursements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therapy termination rates were highest in younger or older patients with ≥1 comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence: five-year PAP persistence under telemonitoring and pay-for-performance in France
“A total of 84,550 patients (63.7% men, mean age 58.5 years, 53.6% with obesity, mean apnea-hypopnea index 40 events/h) were included; 95.7% used telemonitoring.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PAP therapy persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Main documented reasons for stopping PAP were issues with PAP treatment (54.9%), changes in treatment needs (9.3%) and death (7.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, solutions are needed for patients who have PAP-related issues and to further reduce the therapy termination rate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Oral appliance therapy
VA/DoD guideline: mandibular advancement devices or PAP as first-line options for mild to moderate OSA (weak for)
AASM and AADSM guideline: oral appliances for adults intolerant of CPAP or preferring alternate therapy (standard)
“We recommend that sleep physicians consider prescription of oral appliances, rather than no treatment, for adult patients with obstructive sleep apnea who are intolerant of CPAP therapy or prefer alternate therapy. (STANDARD)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When oral appliance therapy is prescribed by a sleep physician for an adult patient with obstructive sleep apnea, we suggest that a qualified dentist use a custom, titratable appliance over non-custom oral devices. (GUIDELINE)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that sleep physicians conduct follow-up sleep testing to improve or confirm treatment efficacy, rather than conduct follow-up without sleep testing, for patients fitted with oral appliances. (GUIDELINE)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The PubMed database was searched from January 1, 2004, through July 31, 2012, and was updated again on February 28, 2013, to capture the latest literature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASM and AADSM guideline: AHI reduction with oral appliances compared with CPAP, pooled trials, hypopnea scoring rule not stated
“In weighted analysis, OAs produced a significant mean reduction in AHI, however the mean reduction in AHI was 6.24 events/h (95% CI: 8.14, 4.34) greater with CPAP than with OA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with moderate to severe OSA, however, the odds of achieving the target AHI were significantly greater with CPAP than with OAs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A review of the evidence suggests that adherence rates using OAs are greater than those observed with CPAP. However, no randomized controlled trials have assessed objective OA adherence rate as compared with CPAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although they are not as efficacious as PAP therapy, the benefits of using OAs outweigh risks of not using OAs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ACP guideline: mandibular advancement devices as an alternative to CPAP (weak recommendation, low-quality evidence)
“RECOMMENDATION 3: ACP recommends mandibular advancement devices as an alternative therapy to continuous positive airway pressure treatment for patients diagnosed with OSA who prefer mandibular advancement devices or for those with adverse effects associated with continuous positive airway pressure treatment. (Grade: weak recommendation; low-quality evidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ERS guideline: CPAP over mandibular advancement devices, with equivalence in mild to moderate OSA (conditional recommendation, very low quality of evidence)
“We systematically searched the following databases from 1 January 1946 until 15 June 2020: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adult patients with OSA, we suggest that CPAP should be used as compared to MAD (conditional recommendation, very low quality of evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, those considerations lead the panel to regard CPAP and MAD as equal in patients with mild to moderate OSA. With increasing severity of OSA, comorbidities or odontological concerns, CPAP should be considered in this group of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weight management and incretin-based pharmacotherapy
VA/DoD guideline: evidence-based weight management combined with other OSA treatment (weak for)
ATS guideline: comprehensive lifestyle intervention (strong), antiobesity pharmacotherapy evaluation (conditional), and bariatric surgery referral (conditional)
ATS guideline: literature search dates and pharmacotherapies reviewed
ACP guideline: weight loss for all adults with overweight or obesity and OSA (strong recommendation, low-quality evidence)
Tirzepatide label: indication for moderate to severe OSA in adults with obesity
Tirzepatide label: dose escalation and OSA maintenance dosage
Tirzepatide label: design of the OSA trials, AHI of at least 15 and BMI of at least 30
Tirzepatide label: week 52 AHI results in Studies 5 and 6, modified intent-to-treat population, hypopneas scored with 4% oxygen desaturation
| Measure | Study 5 placebo (N = 120) | Study 5 ZEPBOUND MTD (N = 114) | Study 5 difference from placebo (95% CI) | Study 6 placebo (N = 114) | Study 6 ZEPBOUND MTD (N = 119) | Study 6 difference from placebo (95% CI) |
|---|---|---|---|---|---|---|
| AHI change from baseline (events/hr) | “-5.3” | “-25.3” | “-20 (-25.8, -14.2)” | “-5.5” | “-29.3” | “-23.8 (-29.6, -17.9)” |
| Percent change in AHI from baseline | “-3” | “-50.7” | “-47.7 (-65.8, -29.6)” | “-2.5” | “-58.7” | “-56.2 (-73.7, -38.7)” |
| Percent of participants with ≥50% reduction in AHI | “19” | “61.2” | “42.8 (30.8, 54.8)” | “23.3” | “72.4” | “48.6 (36.6, 60.7)” |
| Percent with AHI <5 or AHI 5-14 and ESS ≤10 | “15.9” | “42.2” | “28.7 (18.3, 39.2)” | “14.3” | “50.2” | “33.2 (22.1, 44.3)” |
“Data from polysomnographic studies were scored centrally with the use of the American Academy of Sleep Medicine rule 1B for identification of hypopneas (which specifies a ≥30% reduction in airflow for ≥10 seconds and oxygen desaturation of ≥4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SURMOUNT-OSA: AHI change at week 52, treatment-regimen estimand, hypopneas scored with 4% oxygen desaturation
“In trial 1, the mean change in AHI at week 52 was −25.3 events per hour (95% confidence interval [CI], −29.3 to −21.2) with tirzepatide and −5.3 events per hour (95% CI, −9.4 to −1.1) with placebo, for an estimated treatment difference of −20.0 events per hour (95% CI, −25.8 to −14.2) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In trial 2, the mean change in AHI at week 52 was −29.3 events per hour (95% CI, −33.2 to −25.4) with tirzepatide and −5.5 events per hour (95% CI, −9.9 to −1.2) with placebo, for an estimated treatment difference of −23.8 events per hour (95% CI, −29.6 to −17.9) (P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All results are reported with the use of the treatment-regimen estimand unless otherwise specified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 82.9% of the participants completed the trial (91.5% in the tirzepatide groups and 74.4% in the placebo groups) and 79.7% adhered to the assigned regimen (87.6% in the tirzepatide groups and 71.9% in the placebo groups) (Fig. S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SURMOUNT-OSA: AHI change at week 52, efficacy estimand
“For the efficacy estimand, the change in AHI at week 52 was −27.4 events per hour (95% CI, −31.6 to −23.2) with tirzepatide and −4.8 events per hour (95% CI, −9.3 to −0.3) with placebo, for an estimated treatment difference of −22.5 events per hour (95% CI, −28.7 to −16.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the efficacy estimand, the change in AHI at week 52 with tirzepatide was −30.4 events per hour (95% CI, −34.3 to −26.5) with tirzepatide and −6.0 events per hour (95% CI, −10.3 to −1.6) with placebo, for an estimated treatment difference of −24.4 events per hour (95% CI, −30.3 to −18.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SURMOUNT-OSA: percent change in body weight at week 52, treatment-regimen estimand
| Measure | Trial 1 tirzepatide | Trial 1 placebo | Trial 1 difference | Trial 2 tirzepatide | Trial 2 placebo | Trial 2 difference |
|---|---|---|---|---|---|---|
| Percent change in body weight (95% CI) | “−17.7 (−19.0 to −16.3)”View highlighted excerpt for this quote | “−1.6 (−2.9 to −0.2)”View highlighted excerpt for this quote | “−16.1 (−18.0 to −14.2)”View highlighted excerpt for this quote | “−19.6 (−21.0 to −18.2)”View highlighted excerpt for this quote | “−2.3 (−3.8 to −0.9)”View highlighted excerpt for this quote | “−17.3 (−19.3 to −15.3)”View highlighted excerpt for this quote |
AASM provider fact sheet: tirzepatide as part of comprehensive OSA care
AASM guideline: discussion of bariatric surgery referral for adults with BMI of at least 35 who are intolerant or unaccepting of PAP (strong)
“Recommendation 2: We recommend that clinicians discuss referral to a bariatric surgeon with adults with OSA and obesity (class II/III, BMI ≥ 35) who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TF made a strong recommendation in favor of bariatric surgery referral based on moderate-quality evidence from 2 RCTs and 28 observational studies that showed clinically meaningful improvements in several critical outcomes, and the benefits of discussing referral over the harms of no treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, iron malabsorption, gastric ulcer, vitamin deficiency, bowel obstruction or leak, gastrointestinal reflux disorder, and gastric band slippage have been reported but the incidence of these is low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ERS guideline: bariatric surgery evaluation after an unsuccessful weight reduction programme (conditional recommendation, very low quality of evidence), AHI scoring rule not stated
“In adult obese patients with OSA, we suggest bariatric surgery evaluation versus weight-reducing diet when weight has not improved despite participating in a comprehensive weight reduction programme and if there are no contraindications (conditional recommendation, very low quality of evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference between the change scores was −11.5 events·h−1 (95% CI −28.3–5.3 events·h−1), which was not statistically significant (p=0.18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Positional therapy
VA/DoD guideline: positional therapy for positional OSA (weak for), pooled AHI with hypopnea scoring rule not stated
ERS guideline: vibratory positional therapy or CPAP in mild or moderate position-dependent OSA (conditional recommendation, very low certainty of evidence), hypopnea scoring rule not stated
“We suggest either positional therapy using vibratory devices or CPAP among adult patients with mild or moderate position-dependent OSA as defined by a supine AHI at least twice as high as the nonsupine AHI and no relevant nonsupine AHI (<15 events·h−1) (conditional recommendation for either the intervention or CPAP, very low certainty of evidence) (supplementary table e18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with mild positional OSA, we suggest using either vibrational positional therapy or MAD (conditional recommendation for either the intervention or control, very low certainty of evidence) (supplementary table e19).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, positional therapy was superior in terms of compliance (CPAP 4.9 h per night, positional therapy +2.5 h per night; 95% CI 1.3–4.6 h per night).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this context, other studies found the TBT to be associated with low long-term compliance, mostly due to a lack of subjective comfort [85–87].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cochrane review: positional therapy compared with CPAP and with inactive control, pooled AHI with hypopnea scoring rule not stated
“We included eight studies. The studies randomised 323 participants into two types of interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two studies showed that CPAP produced a greater reduction in Apnoea‐Hypopnoea Index (AHI) with a mean difference (MD) of 6.4 events per hour (95% CI 3.00 to 9.79; low‐certainty evidence) compared to positional therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Positional therapy showed a reduction in AHI compared with control (MD −7.38 events per hour, 95% CI −10.06 to −4.7; low‐certainty evidence).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All the studies were of short duration. We are unable to comment on the long‐term effects of the therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypoglossal nerve stimulation
VA/DoD 2025 recommendation for referral after unsuccessful positive airway pressure therapy
FDA device criteria as summarized in the VA/DoD 2025 guideline
Procedure-related and study-related adverse events
ERS 2021 recommendation: salvage treatment rather than first-line treatment
“We suggest that HNS should not be used as first-line treatment for OSA patients in general (conditional recommendation, very low quality of evidence). However, we suggest that HNS compared to no treatment should be considered as a salvage treatment in patients with symptomatic OSA, who cannot be sufficiently treated with positive airway pressure treatment (CPAP, bilevel positive airway pressure) or MAD, and who have an AHI <50 events·h−1 and a BMI <32 kg·m−2 (conditional recommendation, very low quality of evidence) (supplementary table e13).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is limited evidence available for this intervention; a general recommendation was based on selected patients from three RCTs with very strict patient selection (only ∼10% of the screened patients were included) [20, 52, 53].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
STAR trial: eligibility and twelve-month outcomes, AHI scored by a core laboratory with standard criteria
STAR trial: five-year outcomes
“From a cohort of 126 patients, 97 completed protocol, and 71 consented to a voluntary polysomnogram.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AHI response rate (AHI <20 events per hour and >50% reduction) was 75% (n = 71). When a last observation carried forward analysis was applied, the responder rate was 63% at 5 years. Serious device-related events all related to lead/device adjustments were reported in 6% of patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer description of hypoglossal nerve stimulation as an alternative
Upper airway and maxillomandibular surgery
AASM 2021 recommendations on referral for surgical consultation
“We recommend that clinicians discuss referral to a sleep surgeon with adults with OSA and BMI < 40 kg/m2 who are intolerant or unaccepting of PAP as part of a patient-oriented discussion of alternative treatment options (STRONG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that clinicians discuss referral to a sleep surgeon with adults with OSA, BMI < 40 kg/m2, and persistent inadequate PAP adherence due to pressure-related side effects as part of a patient-oriented discussion of adjunctive or alternative treatment options (CONDITIONAL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that clinicians recommend PAP as initial therapy for adults with OSA and a major upper airway anatomic abnormality prior to consideration of referral for upper airway surgery (CONDITIONAL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Evidence base, benefits, and harms of upper airway surgery as rescue therapy
“The TF made a strong recommendation in favor of discussing surgical referral based on a large body of low-quality evidence from 4 randomized controlled trials (RCTs) and 239 observational studies showing clinically meaningful and beneficial differences in nearly all critical outcomes, and the benefits of discussing referral over the harms of no treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses demonstrated a clinically significant reduction in excessive sleepiness, snoring, BP, and AHI/RDI, and a clinically significant improvement in sleep-related and general QOL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, potential persistent long-term side effects have been reported including dysphagia, taste alteration, mandibular paresthesia, perceived worsening of facial appearance, aspiration, hemorrhage, and globus pharyngeus, but the incidence of these is low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A potential limitation regarding this management option is access to a surgeon familiar with the variety of modern surgical techniques for OSA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Maxillomandibular osteotomy compared with CPAP in the ERS 2021 guideline
“50 adults with OSA were randomised to maxillo-mandibular osteotomy (MMO) or auto-adjusting positive airway pressure (auto-adjusting CPAP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“1 year after the intervention, AHI decreased by 48.7 events·h−1 (from 56.8±16.5 events·h−1 to 8.1±7.0 events·h−1), while in the control group it decreased by 44.0 events·h−1 (from 50.3±12.4 events·h−1 to 6.3±1.9 events·h−1). The difference between the score changes was not statistically significant (p=0.21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adult patients with OSA, the task force suggests using either MMO or CPAP (conditional recommendation, very low quality of evidence) (supplementary table e16).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate adverse effects were associated with MMO, which could also require additional orthodontic work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD 2025 recommendation on nasal surgery to support positive airway pressure use
Manufacturer description of surgical options
Wakefulness-promoting agents for residual sleepiness
VA/DoD 2025 recommendation for armodafinil, modafinil, or solriamfetol
Confirming adherence and efficacy of airway treatment before adding a wake-promoting agent
Solriamfetol label: indication and limitation of use in OSA
Armodafinil label: indication and limitation of use in OSA
Wake-promoting agents outside the scope of the ERS 2021 guideline
“In addition, several drugs address the problem of residual sleepiness despite optimal treatment of the underlying disease [103–105]. Unfortunately, these findings could not be included in this project as they do not focus on the causal treatment of the disease itself and major studies were published after the time limit of the literature searches.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
- PAP nonadherence, by definition: with adherence defined as more than 4 hours of nightly use, 46% to 83% of people with OSA have been reported to be nonadherent (Weaver and Grunstein 2008). Relative to a 7-hour night, the overall CPAP non-adherence rate across 20 years of studies was 34.1%, with no significant improvement over that period (Rotenberg et al. 2016). By the CMS definition (at least 4 hours of use on 70% of nights in a consecutive 30-day period within the first 90 days), the observed 90-day adherence rate was 75% (Cistulli et al. 2019), which also cites prior studies in which up to 24% of patients may not fulfill their PAP prescription. The VA/DoD 2025 guideline states that as many as half of patients prescribed PAP have been unable to adopt it long-term. Mean adherence in the CPAP groups of two cardiovascular outcome trials was 3.3 hours per night (McEvoy et al. 2016) and 2.78 hours per night (Sánchez-de-la-Torre et al. 2020).
- PAP termination and persistence: in claims data, with termination defined as cessation of CPAP reimbursements, termination rates among 480,000 people were 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years (Pépin et al. 2021); a second analysis of 174,270 individuals reported a 1-year termination rate of 22.3% (Bailly et al. 2024). Under telemonitoring (95.7% of 84,550 people), PAP persistence was 83.5% at 1 year, 68.4% at 3 years, and 60.5% at 5 years, and issues with PAP treatment accounted for 54.9% of documented reasons for stopping (Baillieul et al. 2026).
- Cardiovascular outcomes: CPAP did not reduce cardiovascular events in randomized trials. In one trial (McEvoy et al. 2016), a primary end-point event occurred in 17.0% of the CPAP group and 15.4% of the usual-care group after a mean 3.7 years (hazard ratio 1.10; 95% CI 0.91 to 1.32). Cardiovascular events occurred in 16% vs 17% in a second trial (Sánchez-de-la-Torre et al. 2020; hazard ratio 0.89; 95% CI 0.68 to 1.17), and the primary endpoint in 18.1% vs 22.1% in a third (Peker et al. 2016; hazard ratio 0.80; 95% CI 0.46 to 1.41). A meta-analysis of 10 randomized trials (7266 participants) found a relative risk of 0.77 (95% CI 0.53 to 1.13) for a composite of acute coronary syndrome, stroke, or vascular death. An individual participant data meta-analysis (4186 participants) found a hazard ratio of 1.01 (95% CI 0.87 to 1.17) for the first major adverse cardiac or cerebrovascular event, and 0.69 (95% CI 0.52 to 0.92) with good adherence in an on-treatment analysis. The AASM guideline finds insufficient and inconclusive evidence to recommend or withhold PAP in non-sleepy adults to reduce cardiovascular events or mortality.
- Oral appliances: in pooled trials (hypopnea scoring rule not stated), the mean AHI reduction was 6.24 events/h greater with CPAP than with oral appliances, and the odds of reaching the target AHI in moderate to severe OSA were greater with CPAP; no randomized trial has compared objective oral appliance adherence with CPAP (AASM and AADSM guideline). The ERS guideline suggests CPAP over mandibular advancement devices (conditional recommendation, very low quality of evidence) and regards the two as equal in mild to moderate OSA.
- Positional therapy: guideline recommendations apply to positional OSA (VA/DoD, weak for) and to mild or moderate position-dependent OSA with a nonsupine AHI below 15 events/h (ERS). In a review of 8 studies (323 participants; hypopnea scoring rule not stated), CPAP reduced the AHI by 6.4 events per hour more than positional therapy (2 studies), all studies were of short duration, and long-term effects could not be assessed. The VA/DoD guideline states that positional therapy was not associated with improved functional outcomes or quality of life, with very low confidence in the evidence.
- Hypoglossal nerve stimulation: the FDA device criteria summarized by the VA/DoD guideline include moderate to severe OSA with an AHI of 15 to 100 events per hour and failure of or intolerance to PAP. The ERS guideline suggests against its use as first-line treatment and suggests it as salvage treatment for patients with an AHI below 50 events/h and a BMI below 32 kg/m2; its trials included about 10% of screened patients. In one randomized trial cited by the VA/DoD guideline, 72.5% of 138 participants experienced a total of 164 procedure- or study-related adverse events. Apnimed cites invasiveness, cost, and BMI and airway collapse pattern exclusions, and states that approximately 100,000 patients had received the therapy as of March 2025.
- Tirzepatide: its OSA indication is limited to moderate to severe OSA in adults with obesity, with a reduced-calorie diet and increased physical activity; its OSA trials enrolled adults with an AHI of at least 15 and a BMI of at least 30 kg/m2. The AASM fact sheet states that there is no head-to-head evidence comparing it with other OSA treatments.
- Wake-promoting agents: the solriamfetol and armodafinil labels indicate them to improve wakefulness in OSA and state that neither treats the underlying airway obstruction.
Positive airway pressure nonadherence across studies
“When adherence is defined as greater than 4 hours of nightly use, 46 to 83% of patients with obstructive sleep apnea have been reported to be nonadherent to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term adoption of positive airway pressure in the VA/DoD 2025 guideline
Cardiovascular outcomes with positive airway pressure: SAVE trial
Cardiovascular outcomes with positive airway pressure: meta-analysis of randomized trials
“In this meta-analysis of 10 randomized clinical trials including 7266 patients, there was no significant association of PAP compared with no treatment (or sham PAP) on a composite outcome of acute coronary syndrome events, stroke, or vascular death (relative risk, 0.77 [95% CI, 0.53-1.13]). There was also no significant association with individual outcomes or all-cause death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insufficient evidence for positive airway pressure to reduce cardiovascular events in non-sleepy adults
Eligibility limits of hypoglossal nerve stimulation and surgery
Wake-promoting agents do not treat airway obstruction
No pharmacotherapy approved for OSA without obesity before tirzepatide, manufacturer statement
Limited applicability of current alternatives in an editorial on SynAIRgy
Place in treatment, anticipated use, and care setting
Summary
- Guideline sequencing: the VA/DoD 2025 algorithm prescribes PAP as first-line therapy for severe OSA (AHI above 30 events per hour) and PAP or a mandibular advancement device for an AHI of 5 to below 30, and refers patients who do not adopt or use PAP or a mandibular advancement device to a sleep medicine specialist. The ACP recommends CPAP as initial therapy (strong recommendation, moderate-quality evidence) and mandibular advancement devices as an alternative (weak recommendation, low-quality evidence). The AASM and AADSM recommend that sleep physicians consider oral appliances for adults intolerant of CPAP therapy or preferring alternate therapy. After PAP is unsuccessful or not accepted, guidelines suggest referral for hypoglossal nerve stimulation evaluation when the AHI is 15 or more per hour (VA/DoD) and recommend discussing referral to a sleep surgeon when the BMI is below 40 kg/m2 or to a bariatric surgeon when the BMI is 35 kg/m2 or more (AASM). Wake-promoting agents are suggested for residual excessive daytime sleepiness in patients optimally treated with sufficient therapy use (VA/DoD).
- VA/DoD 2025 Recommendation 24 suggests against atomoxetine or a combination of atomoxetine and oxybutynin for OSA (“Weak against”). It rests on 2 randomized trials with mixed results, low confidence in the evidence, and known harms (atomoxetine may increase blood pressure; oxybutynin's anticholinergic effects can increase the risk of falls and cause cognitive impairment). The guideline notes that aroxybutynin is not approved by the FDA. Its evidence review ended on March 31, 2024, and it states that randomized trials of these agents as salvage or adjunctive therapy are needed; Apnimed states that both AD109 phase 3 trials, SynAIRgy and LunAIRo, were completed in 2025.
- AD109 phase 3 population: SynAIRgy and LunAIRo enrolled adults with mild to severe OSA who were intolerant of or refused PAP. PAP failure was defined as no PAP use for at least 3 months before randomization or return or removal of the device, and PAP refusal as refusal of PAP after a positive sleep study or refusal of a recommended sleep study due to unwillingness to consider PAP. In the SynAIRgy intent-to-treat set of 615 participants, 411 (66.8%) had PAP intolerance and 205 (33.3%) PAP refusal.
- Apnimed's stated positioning: the initial launch would focus on the approximately 10.5 million people in the United States diagnosed with OSA but untreated (from a 2025 National Sleep Foundation survey), then on patients using another treatment whose OSA is not fully resolved (as a complement to PAP or GLP-1 therapies), with first-line use as the long-term target. The company presentation describes the target patient as intolerant to PAP (refused or failed), diagnosed within the past 2 years, and without insomnia or active cardiovascular disease. Apnimed plans 125 to 150 field representatives covering 15,000 to 20,000 sleep specialists and high-volume primary care practices. Company-cited surveys report that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it (Wells Fargo, August 2025) and that approximately 80% of 1,500 surveyed patients reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA (SHINE Survey).
- An editorial on SynAIRgy describes AD109 as a likely addition to a multimodal treatment framework, particularly for patients unable or unwilling to use PAP.
VA/DoD 2025 Recommendation 24 against atomoxetine or atomoxetine plus oxybutynin
VA/DoD 2025 guideline: evidence review period and research need, predating AD109 phase 3 results
VA/DoD 2025 treatment sequence and referral to a sleep medicine specialist
Manufacturer positioning: launch focus, then adjunctive and first-line use
Manufacturer description of the target patient
Manufacturer-cited surveys of anticipated prescribing and patient demand
Care setting: sleep specialists and primary care, manufacturer statement
Place in a multimodal treatment framework in an editorial on SynAIRgy
Heterogeneity of treatment effect
Endotypic predictors of complete response to atomoxetine plus oxybutynin, AHI with 3% desaturation or arousal hypopnea rule
“Hypopneas were defined as a reduction in flow ≥ 30% from baseline, lasting at least 10 s, and associated with an arousal from sleep or an oxyhemoglobin desaturation ≥ 3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Figure 5 shows individual data: eight of 14 subjects had a complete response to ato-oxy (50% reduction in AHI from placebo and AHI on drug < 10 events/h). These data show that patients with an AHI on placebo < 40 events/h, Fhypopneas > 65%, and Vpassive > 55% were associated with the best likelihood of complete response on ato-oxy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with relatively lower AHI and less severe upper airway collapsibility had the best chance for OSA resolution with ato-oxy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MARIPOSA post hoc subgroups, AHI with 4% desaturation hypopnea rule
“Post hoc analyses showed no statistically significant differences in AHI4 reduction between subgroups based on age, sex, obesity, or baseline OSA severity (Tables E4–E7 in the online supplement). However, a higher proportion of participants with a baseline AHI4 in the mild to moderate range (AHI4 10–30 events/h) experienced a resolution of OSA (defined as AHI4 <10 events/h) compared with those with a baseline AHI4 in the severe range (AHI4 ⩾30; 52.2% vs. 7%; P = 0.004; Figure E2 in the online supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SynAIRgy prespecified subgroups by sex, severity, and BMI, AHI with 4% desaturation hypopnea rule
“Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3). AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled phase 3 analysis: subgroups by baseline severity under both estimands and by BMI under the on-treatment estimand, AHI with 4% desaturation hypopnea rule
Pooled phase 3 analysis: patient-reported outcomes by baseline sleepiness, treatment policy and on-treatment estimands
Variability in response and symptomatic benefit confined to subgroups in an editorial on SynAIRgy
Atomoxetine plus oxybutynin in Japanese participants: responders within a null trial
“The values of AHI, nadir SpO2 , 3% oxygen desaturation index (ODI), 4% ODI, and SpO2 drop time of <90% did not significantly differ between patients receiving ATO-OXY administration and no medication.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the subanalysis demonstrated an obvious decrease in AHI in five responder patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Future studies for identifying treatment response group characteristics are warranted.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Atomoxetine plus oxybutynin for 30 days in predominantly severe OSA, AHI with 3% and 4% desaturation hypopnea rules
“Thirty-nine people with predominantly severe OSA received 80/5 mg ato-oxy, 40/5 mg ato-oxy, 40/2.5 mg ato-oxy, or placebo nightly for 30 days in a double-blind, randomized, parallel design.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Apnea-hypopnea index (AHI) with 4% oxygen desaturation and hypoxic burden decreased by ∼50% with 80/5 mg ato-oxy from baseline but not versus placebo (e.g., AHI with 3% oxygen desaturation and AHI with 4% oxygen desaturation difference at Night 30 was -8.2 [95% confidence interval, -22.5 to 6.2] and -8.5 [95% confidence interval, -18.3 to 1.3] events/h, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence as a modifier of cardiovascular benefit with positive airway pressure
“The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
AASM 2019 recommendations for educational, behavioral, troubleshooting, and telemonitoring interventions
“We recommend that educational interventions be given with initiation of PAP therapy in adults with OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that behavioral and/or troubleshooting interventions be given during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TF identified 18 RCTs that evaluated the use of some combination of an educational, behavioral, or troubleshooting intervention as an adjunct to initiation of PAP therapy compared to PAP therapy with usual care. Meta-analyses demonstrated a clinically significant improvement in PAP adherence with all three types of interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VA/DoD 2025 recommendation for in-person or telehealth adherence interventions
VA/DoD 2025 recommendation for a short course of eszopiclone to improve positive airway pressure usage
Behavioral intervention effect on CPAP use across studies
Multidisciplinary follow-up of hypoglossal nerve stimulation
Manufacturer plans for telehealth pathways and durable medical equipment provider engagement
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Positive airway pressure: sleepiness, sleep-related quality of life, and blood pressure
“Meta-analyses demonstrated a clinically significant improvement in sleepiness with the use of PAP to treat adults with OSA as compared with no treatment. The overall quality of evidence, based on the critical outcome of sleepiness, was high.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses of sleep-related QOL, as assessed by the Calgary Sleep Apnea QOL Index (SAQLI) and the Functional Outcomes of Sleep Questionnaire (FOSQ), demonstrated a clinically significant improvement. However, meta-analyses of global QOL, as assessed by the SF-36 component scores, demonstrated no clinically significant improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses demonstrated clinically significant BP reductions in nocturnal, daytime, and 24-hour systolic and diastolic BP when all patients in the studies were considered, with the largest effects seen for nocturnal measurements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Positive airway pressure: motor vehicle crash risk
“A meta-analysis of 9 observational studies examining crash risk of drivers with OSA pre- vs. post-CPAP found a significant risk reduction following treatment (risk ratio = 0.278, 95% CI: 0.22 to 0.35; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment targets for residual AHI in the VA/DoD 2025 guideline
Effectiveness accounting for adherence: mean disease alleviation
“Mean disease alleviation is a metric that incorporates adherence and efficacy to estimate real-world effectiveness [11]. Therefore, comparisons among treatments should be based on effectiveness rather than efficacy alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the low adherence rates associated with PAP, a treatment that reduces the AHI to below 10 events/h, or even to a higher residual AHI, could achieve effectiveness similar to that of PAP with a residual AHI below 5 events/h if adherence is substantially better.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote